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INTRODUCTION 
 
In this chapter, an introduction is given to shared decision making and decision aids, 
the BRCA1/2 mutation, genetic testing and counseling, the treatment options for 
BRCA1/2 mutation carriers, and decision analysis. At the end, the structure of this 
thesis is outlined. 
 
Shared decision making and decision aids 
Every day, people are facing choices affecting their health. Decision-making is the 
process of choosing between alternatives. There is a trend towards greater patient 
involvement in treatment decisions. The term shared decision-making refers to the 
process of interaction between patients and their health care providers in making 
treatment decisions. Shared decision making addresses the ethical need to fully inform 
patients about the risks and benefits of the treatment options, as well as the need to 
ensure that patients' values play a prominent role. For medical decisions with more 
than one reasonable option, patient participation in decision-making is often necessary 
to optimally match treatment decisions with patient values.  
The actual tools to help with shared decision-making are called decision aids 
(DAs). DAs can include several formats, for instance, brochures, videotapes, decision 
boards, or interactive computer programs. DAs have been defined as “interventions 
designed to help people make specific and deliberative choices among options by 
providing information on the options and outcomes relevant to a person’s health” [1]. 
DAs are designed to help patients to comprehend relevant clinical information, to 
clarify and communicate their personal values, to increase participation in decision-
making, and to arrive at a treatment decision that is consistent with their personal 
values. DAs differ from traditional health education material in a variety of ways. They 
explicitly structure treatment options, including the risks and benefits; they provide 
quantitative rather than qualitative estimates of the risks and benefits; and they tailor 
information to the individual patient whenever possible. Sometimes patients are 
stimulated to think about the personal importance of the risks and benefits of each 
treatment option. Some DAs do this implicitly, by using testimonials from other 
patients. Patients often like to learn from others who have faced the same situation. 
DAs can give a balanced illustration of how others deliberate about treatment options 
and consequences, and arrive at decisions based on their personal situation. Other DAs 
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include explicit value clarification exercises. Values clarification exercises are used to 
explicitly consider and communicate the personal importance of each risk or benefit by 
using strategies as balance scales, relevance charts, or trade off techniques.  
Although the number of published randomized trials assessing the impact of 
DAs on the quality of decision-making is limited, various types of DAs generally do 
appear to improve information uptake in patients when compared with usual care. 
Little evidence is available to determine whether one type of DA is optimal, but more 
complicated programs seem to have larger effects [2]. The use of DAs is usually 
reserved for circumstances in which patients need to carefully deliberate about the 
personal value of the risks and benefits of the various treatment options. Women with a 
BRCA1 or BRCA2 mutation face such a difficult treatment choice between screening 
and prophylactic surgery because of their high risk of breast and ovarian cancer. These 
treatment options have different risk-benefit profiles that women may value differently. 
   
BRCA1/2  
Understanding the significance of mutations in the BRCA1 and BRCA2 genes has 
increased since their localization and cloning in the mid 1990’s [3,4]. Approximately 
5% to 10% of all breast and ovarian cancers can be attributed to an autosomal 
dominant inherited predisposition, with a significant proportion resulting from 
mutations in the BRCA1/2 genes [5-7]. Women with a BRCA1/2 mutation have a 56% 
to 85% lifetime risk of developing breast cancer and 16% to 63% of developing 
ovarian cancer, compared to 11% and 1.8% in the general population [8,9]. The risk of 
developing a second breast cancer is about 60% over a women’s lifetime [10]. 
BRCA1/2 mutations are associated with an early age of onset of breast cancer: a 
woman with a mutation in the BRCA1/2 gene has a 35% to 50% risk of breast cancer 
before she reaches age 50 [8,9]. The age of onset of ovarian cancer associated with 
these mutations is typically later than that of breast cancer [8,9]. Each child of a person 
with a BRCA1/2 mutation has a 50% change of inheriting the mutation. Clues 
suggesting that a BRCA1/2 mutation may be running in a family include: breast cancer 
in several relatives over different generations; early-onset breast cancer; ovarian cancer 
in addition to breast cancer among relatives; relatives who have breast cancer in both 
breasts; male relatives with breast cancer (BRCA2). Genetic susceptibility testing is 
usually recommended if a woman has a 10% chance of having a BRCA1/2 mutation, 
based on her family and personal history of breast and ovarian cancer.  
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Genetic testing and counseling 
The discovery of the BRCA1 and BRCA2 gene mutations has created the possibility to 
test for inherited susceptibility for breast and ovarian cancer. In order to maximize the 
likelihood of obtaining an informative test result, it is recommended that the first 
individual to be tested (index case) has been diagnosed with breast or ovarian cancer. 
When someone with a cancer diagnosis has been tested and found to have a mutation 
in the BRCA1 or BRCA2 gene, the family is said to have a known mutation. Others in 
the family can be tested to see if they have that specific mutation. A positive test result 
indicates that a woman has inherited a BRCA1/2 mutation and is at increased risk for 
developing breast and ovarian cancer during her lifetime, but that there is also a 
possibility that neither of these cancers will develop. A negative test result in a family 
with a known mutation will mean that the tested woman is not at increased risk for 
developing breast or ovarian cancer, her risk is comparable to that in the general 
population. In a family where a mutation has not been identified, a negative test result 
is uninformative, since absence of a detectable mutation in the BRCA1/2 gene does not 
exclude a mutation in another unknown breast cancer predisposition gene that may be 
present within a family. 
The decision to undergo genetic testing is very personal and complex. An 
important reason to ask for genetic testing is to obtain certainty about the need for 
screening and/or prophylactic surgery [11-13]. Women with a BRCA1/2 mutation may 
consider increased screening for breast and ovarian cancer, or potentially consider a 
prophylactic mastectomy or oophorectomy. The family members of a patient with a 
known mutation, who test negative for a mutation, can forego increased screening 
and/or consideration of prophylactic surgery. For women who test positive, decisions 
about prophylactic surgery are not an emergency: women should take time to consider 
the treatment options carefully and make a well informed and deliberative treatment 
choice. 
Before a DNA analysis is offered, it is essential that the patient undergoes 
adequate education and counseling because genetic testing raises important medical, 
psychological, and social issues for themselves and their families. Many institutions 
have developed multidisciplinary programs that involve a variety of health care 
providers. Specialist physicians, psychologists, social workers, clinical geneticists, and 
genetic counselors are often involved in a special Family Cancer Clinic. Each 
professional has an important role in the genetic testing process. The first genetic 
 11 
counseling consultation involves a detailed discussion with a genetic counselor. In the 
Netherlands, these appointments usually lasts approximately one and one-half hours 
and include: (1) discussion of the genetic basis of cancer (2) a detailed evaluation of 
the family history and clarification of the patient’s risk status; (3) detailed discussion of 
the benefits, risks and limitations of genetic testing; (4) discussion of the possible 
treatment options for BRCA1/2 mutation carriers. Furthermore, women are informed 
about the availability of psychological support. Individuals opting for genetic testing 
may have their blood drawn after the consultation. However, many individuals prefer 
to take some time to consider the information provided during the genetic counseling 
consultation and talk to their family members.  
When the mutation is known in the family, a return appointment with the 
clinical geneticist/genetic counselor is made for disclosure of the test result, six to 
eight weeks later. When a mutation is not known in the family, an appointment is made 
after extensive molecular analyses, which may take several months. The results of 
genetic testing are always discussed in person. After a BRCA1/2 mutation is found, 
women are offered follow-up consultations with a multidisciplinary team involved in 
the Family Cancer Clinic generally consisting of a medical oncologist, gynecologist, 
and surgeon. They will further discuss the possible treatment options. 
 
Treatment options 
Clinical expert recommendations for the follow-up care of BRCA1/2 mutation carriers 
have been made in Western Europe and North America [14,15]. At this point in time, 
there are no randomized or long-term studies that have determined which screening or 
prophylactic methods are best for these women. However, retrospective studies have 
shown that prophylactic mastectomy [16,17] and oophorectomy [18] may be effective 
in reducing cancer risk. Recently, short-term prospective studies have also compared 
the efficacy of breast cancer screening and prophylactic mastectomy [19-21]. 
 
Breast cancer screening 
The goal of breast cancer screening is to detect breast cancer as early as possible, when 
the chances for cure are greatest. Based on expert opinion, screening is recommended 
yearly commencing at age 25-30. It is recommended that women at increased risk for 
breast cancer have mammograms once a year and breast exams by a physician at least 
twice a year. In addition, all women should perform monthly breast self-examinations.  
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In a recent study, magnetic resonance imaging (MRI) was found to be superior to 
mammography in women with a hereditary risk of breast cancer [20]. Similarly, other 
studies have found that mammography is a suboptimal screening method in BRCA1/2 
mutation carriers, and that MRI may be superior [21,22]. Such data suggest that MRI is 
likely to be more beneficial than mammography as an early diagnostic tool. These 
results need to be confirmed by larger prospective studies.  
 
Prophylactic mastectomy  
Prophylactic mastectomy is a surgical procedure that removes healthy breast tissue 
before cancer occurs. The nipple and areola are usually removed in order to leave as 
little breast tissue as possible. A variety of techniques for breast reconstruction are 
possible after prophylactic mastectomy. 
Although a woman's chance of developing breast cancer is significantly lower 
after prophylactic mastectomy, the risk is not completely eliminated because it is not 
possible to remove all of the breast tissue. From a retrospective study, prophylactic 
mastectomy reduced the risk of breast cancer by approximately 90% in women at high 
risk for breast cancer [16]. More recent data found that mastectomy was equally 
effective in BRCA1/2 mutation carriers [17]. A recent prospective Dutch study also 
found that prophylactic mastectomy greatly reduces breast cancer risk [19]. However, 
longer follow-up is needed to determine whether the decreased breast cancer risk 
remains throughout a woman’s lifetime.  
Positive outcomes following prophylactic mastectomy include a significant 
reduction in breast cancer risk and a decreased emotional concern about developing 
breast cancer. These must be weighed against the irreversibility of the decision, 
potential problems with (reconstructive) surgery, and a possible alteration of body 
image and self-esteem [23].  
 
Ovarian cancer screening 
Even though a woman with a BRCA1/2 mutation has a lower risk for ovarian cancer 
(16% to 63%) than she has for breast cancer (56% to 85%), ovarian cancer is a big 
concern because it is difficult to detect. Therefore ovarian cancer is more likely to be 
diagnosed at an incurable stage. Screening with pelvic examination, transvaginal 
ultrasound, and blood tests for the CA-125 protein is recommended at least once a year 
generally from age 35, but direct evidence of effectiveness is lacking.  
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One technology that is in its early stages but shows promise is a blood test seeking 
patterns in the proteome of the blood that may reflect the presence of ovarian cancer, 
even at early stages [24]. 
 
Prophylactic oophorectomy 
Prophylactic oophorectomy is a surgical procedure that removes the healthy ovaries 
before cancer occurs. Prophylactic oophorectomy does not completely eliminate 
ovarian cancer risk. Cells that give epithelial ovarian cancer are distributed throughout 
the peritoneum during embryogenesis and cancer may originate in these cells after the 
ovaries have been removed. This type of cancer is known as primary peritoneal cancer.  
Due to the limitations in detecting ovarian cancer at an early stage, prophylactic 
oophorectomy is often a strong consideration for women at high risk of ovarian cancer 
around age 35-40, after childbearing is complete. Two new studies validate this 
approach and support a role for oophorectomy not only in the prevention of ovarian 
cancer but also in reducing the risk of breast cancer [25,26]. These two complementary 
studies have reached the same conclusion: prophylactic oophorectomy reduces the risk 
of ovarian cancer by about 95% and the risk of breast cancer by about 50%.  
Removal of the ovaries eliminates a woman's natural source of estrogen and 
initiates menopause. Women may experience menopausal symptoms, such as hot 
flashes and vaginal dryness, and are at increased risk of cardiovascular events and 
osteoporosis. A difficult issue surrounding prophylactic oophorectomy is the use of 
hormone replacement therapy (HRT). Postmenopausal women are often given HRT to 
alleviate menopausal symptoms and lessen the risks of associated medical problems. In 
the general population, long-term use of HRT has been associated with a small 
increase in breast cancer risk. Currently, little is known about the effects HRT in 
BRCA1/2 mutation, although a retrospective study showed that the use of HRT did not 
negate the reduction in breast cancer risk after prophylactic oophorectomy [27]. 
 A recent study demonstrated that prophylactic oophorectomy is successful in 
reducing anxiety about ovarian cancer [28]. The results also suggested that the benefit 
of anxiety reduction outweighed the potentially adverse effects of the procedure, given 
that women expressed a high level of satisfaction. 
  
Decision analysis 
The choice between screening and prophylactic surgery involves tradeoffs of the risks 
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and benefits of the treatment options. Individual women may differ substantially in 
how they value the effects of the treatment options on their quality of life. Decision 
analysis has the advantage of being able to integrate the benefits and risks of treatment 
options and patient values. The three basic components of decision analysis include the 
decision tree, which summarizes the relevant choices and outcomes, the probabilities 
associated with the occurrence of each outcome, and the patients values for each 
outcome. Decision analysis can provide guidance for counseling individual women by 
estimating the effects of the treatment options on life expectancy and quality adjusted 
life expectancy.  
 
Aim of the thesis 
The focus of this thesis is the evaluation of a shared decision making program, 
consisting of two decision aids, in women testing for a BRCA1/2 mutation. Women 
with a BRCA1/2 mutation face the difficult choice between screening and prophylactic 
surgery for the breasts and/or ovaries. The decision aids were developed to prepare 
women to participate in these value sensitive decisions. Both decision aids were aimed 
to improve decision-making on a broad range of outcomes. The decision aids were 
evaluated in longitudinal randomized trial. Data were collected using questionnaires.  
 
Outline of thesis 
Chapter 2 describes the development of a decision model for BRCA1 mutation 
carriers. This decision model compared life expectancy and quality adjusted life 
expectancy following four treatment options: (1) prophylactic mastectomy and 
prophylactic oophorectomy, (2) prophylactic mastectomy and ovarian cancer 
screening, (3) breast cancer screening and prophylactic oophorectomy, (4) breast- and 
ovarian cancer. This decision analysis will be used within the framework of a shared 
decision making intervention (chapter 5).  
Chapter 3 investigates the differences between women affected and unaffected with 
breast and ovarian cancer immediately after blood sampling for BRCA1/2 testing and 
after a positive test result with respect to well-being, treatment choice, and decision 
related outcomes.   
Chapter 4 consists of the evaluation of an informative decision aid and its timing in 
women testing for a BRCA1/2 mutation. The decision aid consisted of a brochure and 
video, providing information on the various treatment options and outcomes. The 
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decision aid was provided either before or after a positive test result. 
Chapter 5 consists of the evaluation of a shared decision making intervention (SDMI) 
in BRCA1/2 mutation carriers. The SDMI consisted of two value assessment sessions, 
using the time trade-off method, followed by individualized treatment information 
based on life expectancy and quality adjusted life expectancy derived from decision 
analyses.  
Chapter 6 consists of the evaluation of newly constructed Decision Evaluation scales. 
The objective was to investigate which psychological factors play a role when patients 
evaluate their medical treatment choices. The new scales were validated, and their 
performance was contrasted with commonly used measures.  
Chapter 7 concludes the thesis with a discussion on the findings obtained in the 
previous described studies.      
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ABSTRACT 
 
Purpose: BRCA1 mutation carriers have a high risk of developing breast and ovarian 
cancer. Carriers may opt for prophylactic surgery and screening. Recent data 
suggesting that prophylactic oophorectomy reduces breast cancer risk have been 
incorporated in a decision analysis. 
Methods: A Markov model was developed to compare LE and QALE following four 
strategies: (1) prophylactic mastectomy and prophylactic oophorectomy (PMPO), (2) 
screening for breast cancer and prophylactic oophorectomy (BSPO), (3) prophylactic 
mastectomy and screening for ovarian cancer (PMOS), and (4) screening for breast and 
ovarian cancer (BSOS). The analysis was performed for a high (85% breast cancer, 
63% ovarian cancer) and medium (56% breast cancer, 16% ovarian cancer) risk level. 
Utilities for the health states after prophylactic surgery were obtained from mutation 
carriers. Other model parameter values were obtained from the literature. Sensitivity 
analyses were performed.  
Results: When compared with BSOS, the average gain in LE for 30-year-old carriers in 
the high (medium) risk group was 11.7 (6.6) years for PMPO, 9.5 (5.3) years for 
BSPO, and 4.9 (4.4) years for PMOS. For 30-year-old carriers, BSPO had a QALE 
advantage when PO was performed before age 40. In the medium risk group, there was 
a stronger advantage for BSPO when QALE was considered.  
Conclusion: PMPO is the most effective strategy to prolong life. However, if patient 
preferences were taken into account, BSPO tends to be a better strategy in most women 
at medium risk or in young women at high risk when PO was performed before age 40.  
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INTRODUCTION 
 
The discovery of the BRCA1 gene has created the possibility to test for inherited 
susceptibility for breast and ovarian cancer [1]. Between 5% and 10% of all breast and 
ovarian cancer cases in the general population are estimated to be carriers of a 
breast/ovarian cancer susceptibility gene [2-4]. Women with a BRCA1 mutation run a 
high risk of developing breast cancer (56% to 85%) and ovarian cancer (16% to 63%); 
these risk estimates vary depending on the population studied [2, 5-7]. 
Options available to women with a BRCA1 mutation include intensive 
screening programs and prophylactic surgery of the breasts and/or ovaries [8]. BRCA1 
mutation carriers seem to be more interested in prophylactic oophorectomy than in 
prophylactic mastectomy [9,10].  
Knowledge of the long-term efficacy of these strategies in women with a 
BRCA1 mutation is still evolving and the optimal strategy for management of these 
women remains to be established. Recent data suggest that prophylactic oophorectomy 
performed before the age of natural menopause is associated with a 43% reduction in 
breast cancer risk in BRCA1 mutation carriers, irrespective of the use of hormone 
replacement therapy [11]. In a follow-up study, Eisen et al [12] reported a breast 
cancer risk reduction of 76% if oophorectomy was performed before age 40. These 
findings are in line with the substantial breast cancer risk reduction after oophorectomy 
found in the general population [13-15]. If indeed oophorectomy performed before age 
40 substantially reduces breast cancer risk in BRCA1 mutation carriers, the benefit of 
prophylactic mastectomy in addition to prophylactic oophorectomy will be smaller. 
Prophylactic oophorectomy in BRCA1 mutation carriers is currently performed 
to reduce ovarian cancer risk. Oophorectomy is generally postponed up to age 35 to 40, 
after completion of childbearing, and can usually be done by laparoscopy, with 
minimal morbidity. If hormone replacement therapy is administered, long-term effects 
on the cardiovascular system and bone density will be limited and the effects on quality 
of life may be mitigated [16-19].  
Decision analysis offers a method to balance benefits and drawbacks of 
screening and prophylactic surgery in a systematic and structured way [20-24]. An 
important aspect of decision analysis is the inclusion of measures of subjective well 
being (utilities) in the decision. For this specific decision, utilities were shown to be 
important [21,22,24]. Previous decision analyses did not include utilities assessed in 
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BRCA1/2 mutation carriers but used utilities assessed in substitute subjects from 
various backgrounds [21,22,24]. We, however, assessed utilities of prophylactic 
surgery in 23 proven presymptomatic BRCA1/2 mutation carriers. The present decision 
analysis, therefore, improves on previous decision analyses on two major points: it 
takes the interaction between oophorectomy and breast cancer risk into account and it 
incorporates utilities assessed in BRCA1/2 mutation carriers. 
 
METHODS 
 
Design of the model 
A Markov model employing tunnel states was constructed, using Data 3.0.18 software 
(TreeAge Software, Inc, Cambridge, MA) [25]. The model compared four strategies, 
(1) prophylactic mastectomy and prophylactic oophorectomy (PMPO), (2) screening 
for breast cancer and prophylactic oophorectomy (BSPO), (3) prophylactic mastectomy 
and screening for ovarian cancer (PMOS), and (4) screening for breast and ovarian 
cancer (BSOS), with respect to their effect on life expectancy (LE) and quality-
adjusted life expectancy (QALE) for women with a BRCA1 mutation.  
 
 
Figure 1. Representation of the Markov model. Health states are denoted by ovals. Each year, a hypothetical 
cohort of women with a BRCA1 mutation can move from one health state to another or stay in the same health 
state according to the arrows, with variable transition probabilities. * The health state “well” includes four health 
states: well after each of the four strategies. 
Well*
BC OC 
BCOC OCBC 
Meta BC Meta OC 
Death
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Eleven possible health states were defined (Figure 1). A hypothetical cohort of BRCA1 
mutation carriers moves yearly between health states according to the transition 
probabilities. We followed our cohort to age 90 years. Future life years were not 
discounted. Probability estimates for other model parameters were obtained from a 
review of the literature and are described in the next paragraph. Sensitivity analyses 
were performed to assess the effects of plausible parameter changes on the outcome 
[26]. The parameter value that brings about a change in preferred strategy is known as 
the threshold value. Baseline values and plausible ranges of model parameters are 
listed in Table 1. The age-specific annual risk of dying from all causes was taken from 
official statistics [27].  
 
Model parameters  
Breast/ovarian cancer risk. Two risk levels were modeled. The high-risk level (85% 
cumulative risk of breast cancer and 63% cumulative risk of ovarian cancer by the age 
of 70) was based on the data of Easton et al [5]. The medium-risk level (56% 
cumulative risk of breast cancer and 16% cumulative risk of ovarian cancer by the age 
of 70) was reported by Struewing et al [6]. We extrapolated the cumulative risks to age 
90 years.  
Protective effect of prophylactic surgery. Based on the data of a retrospective 
cohort study of women at high risk for breast cancer at the Mayo Clinic, we assumed 
that prophylactic mastectomy reduces the risk of breast cancer by 90% [28]. More 
recent data found that mastectomy was equally effective in BRCA1/2 mutation carriers 
[29,30].  
On the basis of data from the Gilda Radner Familial Ovarian Cancer Registry, 
we estimated a 95% reduction in ovarian cancer risk after prophylactic oophorectomy 
[31]. At the time of publication of the Gilda Radner data the BRCA1/2 mutations were 
not yet cloned, so that the proportion of carriers in this database is unclear. However, 
Weber et al [32] confirmed this estimate more recently in BRCA1/2 mutation carriers. 
We will refer to ovarian cancer developing after prophylactic oophorectomy as primary 
peritoneal carcinoma. 
We assumed that oophorectomy performed before the age of 40, between ages 
40 to 49, and after age 50 reduces breast cancer risk by 76%, 40%, and 6%, 
respectively [12]. This breast cancer risk reduction associated with oophorectomy at 
different ages was found in a follow-up of the study of Rebbeck et al [11], who found a 
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43% risk reduction before age 50 in BRCA1 mutation carriers.  
We assumed that prophylactic oophorectomy in premenopausal women is 
accompanied with hormone replacement therapy until the age of natural menopause. 
We assumed that hormone replacement therapy will not negate the reduction in breast 
cancer risk and reduces the risk of developing osteoporosis and cardiovascular diseases 
to the general population level. 
The Early Breast Cancer Trialists’ Collaborative Group reported a risk reduction 
of breast cancer recurrence after oophorectomy of 26% among women aged under 50 
[33]. It is now recognized that adjuvant hormonal interventions are only of benefit in 
women with estrogen receptor-positive tumors. BRCA1-associated breast cancers have 
been associated repeatedly with estrogen receptor negativity [34,35]. The frequency of 
estrogen receptor positivity in BRCA1 mutation carriers was found to range between 
32% and 36%, whereas the incidence in sporadic cases ranged between 63% and 65%. 
Because the incidence of estrogen-positive tumors in BRCA1 mutation carriers is 
about half of that in sporadic tumors, we assumed a risk reduction of 13% as a baseline 
value [36,37]. Among women aged over 50, we assumed no effect of oophorectomy on 
breast cancer recurrence. 
Treatment of breast and ovarian cancer. The contralateral breast cancer risk for 
BRCA1 mutation carriers with a first primary breast cancer has been estimated to be as 
high as 60% [5]. Although preliminary data suggested that breast conservation therapy 
is safe in BRCA1/2 mutation carriers, we assumed that bilateral mastectomy is 
performed if breast cancer is diagnosed. This is the treatment of choice in most 
European Family Cancer Clinics because of the high risk of multiple ipsilateral 
primaries and contralateral cancer [38]. Although contralateral prophylactic 
mastectomy has not been incorporated into standard practice in North America, there is 
a tendency towards more aggressive surgery in BRCA1 mutation carriers with breast 
cancer [39]. Surgical treatment of ovarian cancer includes at least bilateral salpingo-
oophorectomy and hysterectomy.  
Cancer survival data. Screening recommendations in BRCA1-positive women 
include biannual palpation and yearly mammography beginning at age 25 to 30 years. 
Brekelmans et al [40] found a lower sensitivity of screening in BRCA1/2 mutation 
carriers compared with population screening data. Nevertheless, they and others found 
no significant differences in survival between women with BRCA1-associated and 
sporadic breast cancer despite the biologic indicators of poor outcome among BRCA1-
  25
associated breast cancer. [36,41-46]. Because it is still uncertain whether screening in 
BRCA1/2 mutation carriers contributes substantially to early detection of breast 
cancer, we based our survival on the United States National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) data for 1973 to 1998 [47].  
Data on the prognosis of BRCA1-associated ovarian cancer were obtained from 
Rubin et al [48] who found a better prognosis for BRCA1-associated ovarian cancer 
than for sporadic ovarian cancer. We did not adjust for ovarian cancer screening 
because there is no evidence that vaginal ultrasound or CA-125 measurement alters the 
prognosis of ovarian cancer. The prognosis of primary peritoneal carcinoma is reported 
to be worse than the prognosis of ovarian cancer [49-51]. 
 
Table 1. Baseline values and ranges of the model parameters  
Model parameter Baseline Range Reference 
Prophylactic mastectomy, %    
     Reduction in breast cancer risk 90   75-100 28 
Prophylactic oophorectomy, %    
     Reduction in ovarian cancer risk 95 50-95 31 
     Reduction in breast cancer risk if performed before age 40 
          Between age 40-49 
          After age 50  
76 
40 
  6 
40-90 
 
 
12 
 
 
     Reduction in breast cancer recurrence if performed before age 50 
          After age 50 
13 
  0 
  0-30 33,36,37 
Breast cancer, %    
     10-year disease-specific survival 76 65-95 47 
Ovarian cancer, %    
     10-year disease-specific survival 49 20-93 48 
     5-year survival of primary peritoneal carcinoma 18   2-38 49-51 
Utilities    
     u(prophylactic mastectomy and prophylactic oophorectomy) 0.92 0.50-1.00 * 
     u(screening for breast cancer and prophylactic oophorectomy) 0.99 0.50-1.00 * 
     u(prophylactic mastectomy and screening for ovarian cancer) 0.93 0.50-1.00 * 
     u(screening for breast and ovarian cancer) 1.00 0.50-1.00 * 
     u(breast cancer) 0.95 0.50-1.00 * 
     u(ovarian cancer)  0.77 0.50-1.00 22,53 
     u(metastatic breast or ovarian cancer) 0.66 0.50-0.80 22,53 
NOTE. Ranges are presented for cohorts of 30-year-old BRCA1 mutation carriers with prophylactic 
oophorectomy performed at age 35. 
*Utilities assessed in BRCA1/2 mutation carriers in an ongoing study (unpublished results). 
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Utilities. A utility is the subjective value given to a health state. We assessed utilities 
for prophylactic surgery with the time trade-off (TTO) method (Table 1), in which 
quality of life is traded against life duration in a better health state [26]. In our case, the 
better health state was BSOS, and its utility was set equal to 1. A utility of 0.92 for 
PMPO indicates that life after PMPO is subjectively equal to 92% of a life duration in 
the health state BSOS.  
The utilities of prophylactic surgery were assessed in 23 proven carriers of a 
BRCA1 (n=11) or BRCA2 mutation (n=12) with a mean age of 38.5 years (range, 20 
to 58 years). Presymptomatic carriers performed a choice-based TTO assessment in 
two interviews using a visual aid 2 months after they learned their carrier status 
(completion rate: 100%). Health state duration depended on the life expectancy of the 
carriers. These utilities were assessed within an ongoing randomized prospective study 
of the value of a formal shared decision-making program in the choice between 
screening and prophylactic surgery. We also incorporated the utility of breast cancer 
assessed in 12 symptomatic BRCA1/2 carriers 2 months after they received their test 
result. These women were diagnosed with breast cancer without distant metastases 
before blood sampling for genetic testing and had a mean age of 43.8 years (range, 35 
to 55 years). The latter utilities were collected by converting a rating of own health, 
obtained by questionnaire, to a TTO-equivalent utility using a power function [52]. For 
the utility of ovarian cancer and metastases, we calculated a weighted average of the 
TTO estimates from Grann et al [22,53] derived from various populations.  
 
RESULTS 
The gains in LE and QALE after PMPO, BSPO, and PMOS, as compared with BSOS, 
are listed in Table 2 for two risk levels. For BRCA1 mutation carriers aged 30 years, 
we evaluated two additional strategies of delaying prophylactic oophorectomy until age 
35 and age 40.    
 
LE 
The largest gain in LE was found for PMPO for all ages at both risk levels. In the high-
risk group, BSPO showed a larger gain in LE than PMOS. In the medium-risk group, 
BSPO showed a larger gain in LE than PMOS only when prophylactic oophorectomy 
was performed before age 40. For 30-year-old BRCA1 mutation carriers at both risk 
levels, the effect of prophylactic mastectomy is stronger as prophylactic oophorectomy 
is delayed. 
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QALE 
For 30-year-old BRCA1 mutation carriers in the high-risk group, QALE gains were 
largest after BSPO when prophylactic oophorectomy was performed before age 40. 
When prophylactic oophorectomy was delayed until age 40, PMPO led to the highest 
gain in QALE. For all other ages in the high-risk group, PMPO showed the largest 
gain. BSPO led to higher QALE gains than PMOS.  
For 30-year-old BRCA1 mutation carriers in the medium-risk group, QALE 
gains were also largest after BSPO when prophylactic oophorectomy was performed 
before age 40. PMPO also led to the highest gain in QALE when prophylactic 
oophorectomy was delayed to age 40. Contrary to the high-risk group, BSPO showed 
the largest gain in QALE for all other ages. In the medium-risk group, BSPO also led 
to larger QALE gains than PMOS. For the age groups 50 and 60 years, PMOS led to 
QALE losses.  
 
Table 2. Age-specific gains in LE and QALE after PMPO, BSPO, and PMOS, for the high- and medium-risk 
level 
   BSOS PMPO BSPO  PMOS  
Age PM Age PO  Total Gains in: Gains in:  Gains in: 
Risk level (years) (years)  LE QALE LE QALE LE QALE  LE QALE
High* 30 30  37.6 35.5 11.7 9.8 9.5 10.7  4.9   2.8 
 30 35  37.6 35.5 11.5 9.7 8.7   9.8  4.9   2.8 
 30 40  37.6 35.5 11.1 9.2 5.9   6.7  4.9   2.8 
 40 40  29.3 27.3 10.1 8.9 6.5   7.4  3.7   2.2 
 50 50  24.6 23.2  5.8 4.7 3.2   3.6  1.8   0.5 
 60 60  17.1 15.8  4.6 4.1 2.5   3.0  1.4   0.6 
Medium† 30 30  43.6 42.5  6.6 3.7 5.3   5.7  4.4   1.9 
 30 35  43.6 42.5  6.5 3.6 4.7   5.1  4.4   1.9 
 30 40  43.6 42.5  6.2 3.4 2.9   3.0  4.4   1.9 
 40 40  35.2 34.1  5.2 3.0 3.0   3.3  3.4   1.4 
 50 50  28.8 28.2  2.3 0.4 0.9   0.9  1.4 - 0.3 
 60 60  20.5 20.0  1.7 0.4 0.7   0.7  1.0 - 0.1 
NOTE. BSOS is used as the reference strategy. The strategy with the largest (QA)LE is indicated in bold. 
Negative numbers represent a loss in QALE. 
Abbreviations: PM, prophylactic mastectomy; PO prophylactic oophorectomy. 
*High-risk level = 85% breast cancer and 63% ovarian cancer.                      
†Medium-risk level = 56% breast cancer and 16% ovarian cancer. 
 
Sensitivity analyses 
As illustrated in Table 2, gains in LE and QALE are sensitive to age, age of 
performing prophylactic oophorectomy, and risk level.  
 Table 3. Effect on LE in 30-year-old BRCA1 mutation carriers (PO at age 35) at high risk (85% breast cancer and 63% ovarian cancer) for varying the six 
most important clinical parameters 
    BSOS  PMPO BSPO PMOS 
 Baseline Range Threshold LE  Gains in LE 
Reduction in ovarian cancer risk after PO  95%   50% 
  95% 
- 37.6 
37.6 
   5.1 
11.5 
2.9 
8.7 
4.9 
4.9 
Median age of incidence of ovarian cancer    - 10 yrs 
  +10 yrs 
- 35.2 
39.5 
 10.3 
10.1 
7.7 
7.2 
4.3 
5.8 
Reduction in breast cancer risk after PM 90%   75% 
100% 
- 37.6 
37.6 
 11.0 
11.9 
8.7 
8.7 
3.8 
5.7 
Reduction in breast cancer risk after PO  76%   40% 
  90% 
- 37.6 
37.6 
 11.2 
11.7 
6.4 
9.8 
4.9 
4.9 
Median age of incidence of breast cancer    - 10 yrs 
  +10 yrs 
- 35.8 
40.0 
 13.1 
  9.4 
8.6 
8.0 
6.4 
3.0 
10-year breast cancer specific survival 76%   65% 
  95% 
- 35.4 
42.1 
 13.6 
  7.4 
9.7 
6.7 
6.8 
1.1 
NOTE. The preferred strategy is indicated in bold. When baseline values are used, the preferred strategy is PMPO.   
Abbreviations: PO, prophylactic oophorectomy; PM, prophylactic mastectomy. 
  
 
Table 4. Effect on QALE in 30-year-old BRCA1 mutation carriers (PO at age 35) at high risk (85% breast cancer and 63% ovarian cancer) for varying the 
parameters affecting the preferred strategy 
    BSOS  PMPO BSPO PMOS 
 Baseline Range Threshold QALE  Gains in QALE 
u(PMPO) 0.92 0.50 
1.00 
> 0.92 35.5 
35.5 
 - 10.5 
  13.5 
  9.8 
  9.8 
   2.8 
   2.8 
10-year breast cancer specific survival 76% 65% 
95% 
< 75% 33.4 
39.8 
   11.7 
    5.7 
10.7 
  8.0 
   4.6 
- 1.0 
Median age of incidence of breast cancer   - 10 yrs 
 +10 yrs 
    > -1.7 yrs 33.6 
38.0 
   11.4 
    7.4 
  9.7 
  9.2 
   4.5 
   0.7 
Reduction in breast cancer risk after PO 76% 40% 
90% 
< 74% 35.5 
35.5 
     9.4 
    9.8 
  7.2 
11.1 
   2.8 
   2.8 
u(breast cancer) 0.95 0.50 
1.00 
< 0.93 31.6 
36.0 
   13.2 
    9.3 
10.7 
  9.7 
   6.1 
   2.4 
Reduction in breast cancer recurrence after PO 13%   0% 
30% 
< 7% 35.5 
35.5 
     9.7 
    9.8 
  9.5 
10.3 
   2.8 
   2.8 
u(BSPO) 0.99 0.50 
1.00 
< 0.99 35.5 
35.5 
     9.7 
    9.7 
- 9.2 
10.2 
   2.8 
   2.8 
Reduction in breast cancer risk after PM 90% 75% 
100% 
> 94% 35.5 
35.5 
     9.2 
  10.0 
  9.8 
  9.8 
   1.9 
   3.5 
NOTE. The preferred strategy is indicated in bold. When baseline values are used, the preferred strategy is BSPO.   
Abbreviations: PO, prophylactic oophorectomy; PM, prophylactic mastectomy. 
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To study the stability of the results, sensitivity analyses were performed for cohorts of 
30-year-old BRCA1 mutation carriers in both risk groups assuming that oophorectomy 
is delayed to age 35 years.  
LE. No thresholds were found for any of the parameters, neither in the high- nor 
medium-risk group, indicating that there is no change in preferred strategy within the 
range of values studied. For the high-risk group, Table 3 lists the effect on LE for each 
strategy when a range of different values is used for the six most important parameters. 
The same six parameters were also found to be most important for the medium-risk 
group (results not tabulated). 
QALE. For the high-risk group, many thresholds were found. Table 4 lists the 
effect on QALE and the threshold value for the parameters affecting the preferred 
strategy. Some threshold values are very close to the baseline value, indicating that 
small changes in these parameters will lead to a change in the preferred strategy. For 
example, a decrease in 10-year breast cancer-specific survival from 76% to 75% or 
lower will cause the preferred strategy to switch from BSPO to PMPO. In the medium-
risk group, the results were more stable. Threshold values, leading to a change in 
preferred strategy from BSPO to PMPO, were only found for the utility PMPO (> 
0.95), the reduction in breast cancer risk after prophylactic oophorectomy (< 62%), the 
utility for BSPO (< 0.96), and the utility for breast cancer (< 0.51). Both the analyses 
for the high- and medium-risk groups indicated that individual values play a crucial 
role in the decision. 
 
DISCUSSION 
 
The present decision analysis is the first to explore the effects of the recently reported 
interaction between oophorectomy and breast cancer risk on LE and QALE in BRCA1 
mutation carriers [11,12]. Furthermore, it is the first analysis that incorporates utilities 
for prophylactic surgery assessed in proven BRCA1/2 mutation carriers. The results 
point towards a more prominent role of oophorectomy alone as a prophylactic strategy.  
Previous decision analyses found that prophylactic mastectomy alone results in 
a larger gain in LE than prophylactic oophorectomy alone in both high- and medium-
risk groups [20,22-24]. A previous study reported smaller gains for 30-year-old 
mutation carriers from a comparable high-risk group for all strategies [22]; 
prophylactic mastectomy alone yielded 2.8 years compared with 4.9 years found in our 
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analysis; prophylactic oophorectomy alone (at age 30) yielded 2.6 years compared with 
9.5 years found in our analysis; and the combination of both types of surgery yielded 
6.0 years compared with the 11.7 years reported here. For 30-year-old mutation carriers 
in the medium-risk group, we found gains comparable with those previously reported 
[20,21,24]. For prophylactic oophorectomy alone however, we found larger gains.  
Our larger gains after prophylactic oophorectomy are a result of including the 
interaction between oophorectomy and breast cancer risk. Removal of ovarian tissue 
reduces estradiol levels, inducing menopause. As a result, both breast and ovarian 
cancer risk may be lowered [54]. By assuming no effect of oophorectomy on breast 
cancer risk, previous studies may have overestimated the additional effect of 
prophylactic mastectomy and underestimated the effect of prophylactic oophorectomy 
[22,22-24]. Tengs et al [21] assumed that oophorectomy reduces breast cancer risk by 
as much as 9% to 25% based on expert opinion. We, however, assumed a greater 
reduction in breast cancer risk after oophorectomy, especially when oophorectomy is 
performed before age 40, based on estimates from Eisen et al [12]. These estimates by 
age category on breast cancer risk reduction associated with oophorectomy in 
BRCA1/2 mutation carriers are based on a follow-up study of Rebbeck et al [11]. Their 
findings are in agreement with a report showing that oophorectomy reduces the risk of 
contralateral breast cancer in BRCA1/2 mutation carriers [55]. Oophorectomy also 
reduces breast cancer risk in premenopausal women unselected for breast cancer risk 
[13-15]. Although further studies are needed to confirm the efficacy of prophylactic 
oophorectomy in reducing breast cancer risk, the potential implications for BRCA1 
mutation carriers are important.   
We did not evaluate the protective effect of tamoxifen on breast cancer risk in 
our decision model because mixed results were reported [56-58]. None of these studies 
have specifically evaluated women with a BRCA1 mutation. Two recent studies 
evaluating the effect of tamoxifen in reducing breast cancer risk and contralateral 
breast cancer risk in BRCA1 mutation carriers also found mixed results [55,59]. Even 
if tamoxifen effectively reduces breast cancer risk in BRCA1 mutation carriers, 
oophorectomy may be a more attractive option because it combines a reduction in 
breast cancer risk with a sharp reduction of the increased ovarian cancer risk.  
A second reason for our different results lies in the expected risk reduction for 
ovarian cancer after oophorectomy. Most decision analyses used a 45% to 50% risk 
reduction of ovarian cancer after prophylactic oophorectomy, as reported by Struewing 
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et al [20,22-24,60]. Tengs et al [21] assumed a risk reduction of 77% to 81% based on 
expert opinion. In the general population, however, primary peritoneal cancer occurs in 
only approximately 5% of all ovarian cancers [61]. This agrees with the result of Piver 
et al [31], who found that approximately 2% of women with a family history of ovarian 
cancer who underwent oophorectomy developed primary peritoneal cancer. Because it 
is very unlikely that all women in this study had a genetic predisposition to develop 
ovarian cancer, 2% is probably an underestimation of the true risk in carriers of a 
BRCA1 mutation. We, therefore, assumed that 5% of all ovarian cancers would 
present as primary peritoneal cancer, which cannot be prevented by oophorectomy. 
This concurs with a risk reduction after oophorectomy of 95%, much larger than used 
previously. Our estimate agrees with the estimate of Weber et al [62] obtained in 
BRCA1/2 mutation carriers.  
A further reason for our different results is that we included the effect of 
oophorectomy on breast cancer recurrence. The observed risk reduction in a meta-
analysis of sporadic breast cancer was 26% among women aged under 50 years [33]. 
We assumed a risk reduction of 13% in our analysis, based on the observation that the 
incidence of estrogen receptor-positive tumors in BRCA1 mutation carriers is about 
half of that seen in sporadic cases [36.37]. 
For the long-term prognosis of breast cancer, we used the most recent SEER 
data [47]. The SEER data represent the long-term breast cancer survival of a large 
population, unselected for screening behavior and family history. It is not clear 
whether these survival data can be safely extrapolated towards an optimally screened 
population of relatively young BRCA1-positive breast cancer patients. Up to now, 
there are several studies that confirm that breast cancer in BRCA1 mutation carriers 
show more unfavorable tumor characteristics than sporadic tumors. However, survival 
was not found to be worse in BRCA1-related breast cancers [36,63].  
The efficacy of screening in BRCA1/2 mutation carriers is uncertain. Although 
screening works for women in the general population aged 50 years and over [64] and 
seems to benefit younger women with a family history of breast cancer [65], it remains 
unclear whether this is also true for BRCA1 mutation carriers, and published studies 
show contradictory results. A recent study observed a lower sensitivity for screening 
and a relatively unfavorable tumor stage at diagnosis in BRCA1 mutation carriers 
compared with an age-matched average-risk population [66], whereas another study 
suggests that screening by annual magnetic resonance imaging (MRI) might indeed 
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improve survival [67]. The favorable effect of screening by MRI in this group of 
women seems to be confirmed by the study of Warner et al [68], who reported the 
detection of all six invasive cancers that developed in a high-risk population by MRI at 
a size of less than 1 cm. Ultrasound, conventional mammography, and palpation could 
detect only three, two, and two of the six cancers, respectively. Larger studies are 
needed to assess the effect of screening and tumor characteristics on survival in 
BRCA1 mutation carriers. We chose to model the survival of breast cancer detected 
during screening in BRCA1 mutation carriers by using the survival of women with 
sporadic breast cancer.  
In our analysis, we incorporated utilities of prophylactic surgery assessed in 23 
proven carriers of a BRCA1/2 mutation 2 months after receiving the test result. These 
utilities were considerably higher than those used in previous decision analyses of 
prophylactic surgery and screening. For example, Grann et al [22,53] reported utilities 
of 0.67 to 0.86 in various groups of substitute subjects for prophylactic mastectomy 
and oophorectomy combined, whereas we found a utility of 0.92 in our group of 
mutation carriers. For the other surgery options, our utilities are also considerably 
higher than those used in previous decision analyses. These higher utilities favor 
surgical strategies. Our utility for breast cancer was obtained from symptomatic 
carriers valuing their actual health; the utility given to breast cancer by presymptomatic 
carriers is probably lower, which can lead to a change in preferred strategy as was 
shown in the sensitivity analyses.  
We conclude that prophylactic oophorectomy alone below age 40 should be 
seriously considered. The negative effects of oophorectomy on quality of life may be 
mitigated by hormone replacement therapy whereas prophylactic mastectomy is an 
irreversible procedure with adverse psychologic and social outcomes in some women 
[19,69]. BRCA1 mutation carriers who have completed their childbearing before age 
40 may, therefore, reasonably consider prophylactic oophorectomy for risk reduction 
of both breast and ovarian cancer. We believe that the potential implications of our 
results, pointing to a more prominent role for prophylactic oophorectomy, should be 
considered in the counseling process.   
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ABSTRACT 
 
To evaluate the impact of BRCA1/2 testing and disclosure of a positive test result on 
women affected and unaffected with cancer. Longitudinal cohort study including 
women affected and unaffected with breast or ovarian cancer testing for a BRCA1/2 
mutation. Data on well-being (anxiety, depression, cancer related distress, general 
health), treatment choice, and decision making about cancer prevention were collected 
at baseline (1 week after blood sampling; affected n = 192, unaffected n = 176) and at 
follow-up (2 weeks after disclosure of a positive test result; affected n = 23, unaffected 
n = 66). Women affected and unaffected with breast or ovarian cancer were compared 
using univariate statistics. Change over time was examined using repeated measures 
analysis of variance. With respect to well-being, affected women scored worse at 
baseline. At follow-up, both affected and unaffected women experienced a decline in 
well-being, which tended to be stronger in affected women. Women diagnosed with 
cancer less than 1 year previously tended to report a worse well-being than those 
diagnosed longer ago. With respect to treatment choice, more affected women intended 
to obtain prophylactic surgery and valued it higher at both time points. With respect to 
decision making, affected women had a lower preference for participation in decision 
making at baseline; no differences were found at follow-up. At follow-up, both 
affected and unaffected women showed an increase in strength of treatment preference 
and a decrease in decision uncertainty. Disclosure of a positive test result had a 
negative impact on well-being. Affected women, especially those who have been 
recently diagnosed with cancer, experienced the worst well-being and could benefit 
from psychosocial support.  
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INTRODUCTION 
 
The identification of the BRCA1 and BRCA2 genes has created the possibility to test 
for inherited susceptibility of breast and ovarian cancer [1,2]. Diagnostic genetic 
testing in a family usually begins in a woman affected with cancer (index case). Once a 
mutation is detected, predictive testing can be performed in other family members. 
Affected mutation carriers have a high risk of developing a second cancer [3]. 
Unaffected mutation carriers have a high cumulative lifetime risk for breast (56 to 
85%) and ovarian cancer (16 to 63%) [3-6]. In the Netherlands, mutation carriers 
currently face the difficult choice between prophylactic surgery and screening of 
breasts and/or ovaries. 
Because genetic testing and disclosure of a positive test result may have far 
reaching consequences for both affected and unaffected women, it is important to 
monitor the impact on well-being and decision making about cancer prevention. A 
priori, one might assume that genetic testing and disclosure of a positive test result may 
cause distress. However, previous studies evaluating the impact of genetic testing and 
disclosure of a positive test result, showed low levels of general and cancer related 
distress [7-13]. Some of these studies evaluated changes in pre- and post-test distress 
and found that mutation carriers showed no significant increase in distress after 
learning their carrier status [7,8,10,12,13].  
Until now, no study specifically concentrated on the differential impact of 
genetic testing on women affected with cancer versus those unaffected. One study, 
including women anticipating and receiving genetic testing, reported that affected and 
unaffected women had similar levels of distress [11]. Another study evaluated the 
impact of a positive test result and found that mutation carriers with a history of cancer 
or cancer-related surgery were less distressed than those without such a history [8]. A 
recent study, including both affected index cases and their unaffected relatives, looked 
at the impact of the test result within those groups and not between those groups [13].   
The purpose of the present study was to evaluate the impact of BRCA1/2 testing 
and disclosure of a positive test result on women affected and unaffected with breast or 
ovarian cancer. We looked at a broad spectrum of outcomes considering well-being 
and decision making. Because little is known about the impact of genetic testing and 
disclosure of a positive test result on affected versus unaffected women, knowledge of 
the levels of distress and the need for help to cope and make decisions may help to 
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improve educational and counseling programs. 
This report is subsumed within a larger randomized controlled trial on shared 
decision making. It was not the primarily objective of that study to focus on the 
differences between women affected and unaffected with cancer. However, because 
we hypothesized that affected women are different from unaffected women with 
respect to well-being and decision making, we conducted an interim analysis to 
compare affected and unaffected women. When resources for supportive services are 
scarce, it is important to distinguish those who might benefit the most from additional 
support.   
 
METHODS 
 
Study population 
Women affected and unaffected with breast or ovarian cancer, who provided a blood 
sample for BRCA1/2 testing at the Family Cancer Clinics of the University Hospitals 
of Nijmegen (accrual started March 1999), Groningen (accrual started June 1999), and 
Maastricht (accrual started January 2000), were eligible for participation. The Eastern 
part of the Netherlands is covered by these three clinics. Study entry closed in 
November 2001. Women were excluded from the study if they were unable to give 
informed consent, had insufficient proficiency of the Dutch language, had distant 
metastases, had undergone bilateral mastectomy and oophorectomy. Women recently 
treated for cancer (less than 1 month ago) were also excluded because we assumed that 
these women were still recovering and were more engaged with the outcomes of the 
curative treatment than with decision making about cancer prevention. 
 
Study procedure 
Data were collected during a longitudinal randomized trial on shared decision making 
including two decision aids. This study was approved by the local research ethics 
committees. This paper only reports the baseline (1 week after blood sampling) and a 
follow-up assessment (2 weeks after disclosure of a positive test result) for affected 
and unaffected women. During this time period, women had received the first decision 
aid either before or after disclosure of a positive test result; this decision aid consisted 
of a brochure and video providing detailed information on prophylactic surgery and 
screening and the consequences. This informative decision aid had positive effects on 
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information related outcomes only, and none, whatsoever, on well-being and decision 
making. Though, it did lead to more considerations towards prophylactic surgery and 
higher valuations for prophylactic surgery and lower valuations for screening. 
Furthermore, because timing of the decision aid had no effect, all women at follow-up 
were equal on the outcome measures [14]. The second decision aid, consisting of value 
assessment and individualized treatment information, will be evaluated only in 
BRCA1/2 mutation carriers. The follow-up time point reported here, will be the 
baseline assessment for this second intervention. 
 Clinical geneticists or genetic counselors briefly introduced the study when a 
blood sample for genetic testing was obtained. A research assistant subsequently 
contacted these women by phone to confirm eligibility and to discuss the study. 
Women who gave verbal consent were enrolled and were mailed an informative letter 
describing the study, a consent form, and the baseline questionnaire. Two weeks after a 
positive test result, women received a follow-up questionnaire by mail. 
 
Standard genetic counseling 
Before a blood sample for genetic testing is taken, usually two counseling sessions 
with a genetic counselor or clinical geneticist take place including the following: 
clarification of the patient's increased risk status, explanation of genetic cancer 
susceptibility, information on the pros and cons of genetic testing, the possible 
outcomes of testing, and limited data regarding cancer screening and prophylactic 
surgery. When a mutation is found, more detailed information is provided on the 
possible treatment options and women are offered additional consultations with 
specialist physicians (medical oncologist, gynecologist, and surgeon). These 
appointments usually take place a few weeks after testing positive for a BRCA1/2 
mutation, this is after the follow-up assessment reported here. A social worker or a 
psychologist is generally present when a positive test result is disclosed to unaffected 
women.  
 
MEASURES 
 
Sociodemographics and medical history 
Data were obtained on sociodemographics (age, marital status, education level, 
employment status, presence of children, wanting (more) children, being religiously 
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affiliated) and medical history (personal and family history of breast/ovarian cancer, 
time since last cancer diagnosis, being an index case, having first degree relatives with 
breast/ovarian cancer, having first degree relatives who died of breast/ovarian cancer). 
 
Well-being 
Anxiety. Anxiety was measured using the 20 items of the State Anxiety scale of the 
Spielberger State-Trait Anxiety Inventory (STAI) [15]. Sum scores on this measure 
range from 20 to 80, with higher scores representing higher levels of anxiety. 
Depression. Depression was measured using the 20 items of the Center for 
Epidemiologic Studies Depression Scale (CES-D) [16]. Sum scores on this measure 
range from 0 to 60, with higher scores reflecting more depressive symptoms. 
Cancer related distress. Cancer related distress was measured with the Impact 
of Event Scale (IES) [17]. The two subscales “intrusion” (seven items) and 
“avoidance” (eight items) measure becoming overwhelmed by thoughts and feelings 
about cancer in the family and a tendency to avoid these thoughts and feelings 
respectively. A four-point response scale ranging from “not at all” to “often” was 
employed and coded 0, 1, 3, and 5. Sum scores on this measure range from 0 to 75, 
with higher scores indicating more distress.  
Adequate reliability rates for the above measures on psychological well-being 
have been reported previously in comparable samples [7,8]. Consistent with past 
studies, the Cronbach’s coefficients alpha in our sample for the STAI-state, CESD and 
IES were 0.95, 0.91, and 0.87, respectively. 
General health. Women were asked to rate their general health state during the 
last week on a 11-point rating scale (0, very bad; 10, excellent). 
 
Treatment choice 
At baseline, women were asked their intended treatment choice if found to be a 
mutation carrier. For the decision related to the breasts and ovaries, the choice was 
between “prophylactic surgery”, “screening”, and “undecided”. At follow-up, mutation 
carriers were asked their intended treatment choice using the same alternatives. To test 
differences in treatment choice, treatment choice was dichotomized into prophylactic 
surgery versus another treatment choice (i.e., “screening” and “undecided”). 
Furthermore, women were asked to value the treatment options “prophylactic 
mastectomy”, “breast cancer screening”, “prophylactic oophorectomy”, and “ovarian 
cancer screening” on a 10-point rating scale (1, very bad; 10, excellent). 
 45 
Decision making 
The following three outcomes were asked separately for the decision related to the 
breasts and ovaries. An overall score was created by adding the scores on the items for 
the decision related to the breast and ovaries and by dividing this sum score by the total 
number of items. 
Strength of treatment  preference. Strength of treatment preference was assessed 
on a four-point Likert scale (1, weak preference; 4, very strong preference). Those who 
had chosen “undecided” as treatment choice were assigned a value of zero (no 
preference).  
Decision uncertainty. Decision uncertainty was measured using three items 
from the uncertainty subscale of the Decisional Conflict Scale by O’Connor [18] and 
adapted for this situation. Our items were: “I doubt what to choose”, “This decision is 
hard for me to make”, and “I am not sure what to choose”. A five-point scale (1, very 
much disagree; 5, very much agree) was used. The Cronbach’s coefficient alpha was 
0.89. 
Preference for decision making. Preference for decision making was measured 
using the following two decision making items from the Problem-Solving Decision-
Making Scale (PSDM) from Deber et al [19]. The items were: “Given the risks and 
benefits of the possible treatment options, who should decide how acceptable those 
risks and benefits are for you”, and “Given the risks and benefits of the possible 
treatment options, who should decide which treatment option should be selected”. A 
five-point scale (1, doctor alone; 3, doctor and I equally; 5, I alone) was used. The 
Cronbach’s coefficient alpha was 0.87. 
 
Statistics 
In multi-item scales with missing data, we calculated scale values if at least half of the 
items were filled out. We used the Statistical Package for the Social Sciences (SPSS 
10.0.5) to analyze the data.  
Descriptive statistics were generated to describe the total sample and the 
subsample of mutation carriers in terms of sociodemographics and medical history. 
Differences between affected and unaffected women on the baseline variables and on 
the outcome variables (at baseline and at follow-up) were explored using univariate 
statistics (t-tests for independent samples and 2-tests). Repeated measures analyses of 
variance were performed to examine change over time (impact of a positive test result) 
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on well-being and decision making, with cancer history (affected versus unaffected) as 
between-groups factor. Levels of P  0.05 (two-tailed) were regarded as statistically 
significant.  
Because a previous study [12] found that women recently diagnosed with cancer 
experienced the greatest distress, additional analyses were done within the group of 
affected women. Differences between women diagnosed with cancer  1 year 
previously and those diagnosed > 1 year in well-being (at baseline and at follow-up) 
were explored using univariate statistics (t-tests for independent samples). We also 
conducted repeated measures analysis of variance to examine change over time (impact 
of a positive test result) on well-being, with time since diagnosis ( 1 year versus > 1 
year) as between-groups factor.  
 
RESULTS 
 
Participants 
During the study period, 453 eligible women were asked to participate in a longitudinal 
randomized trial on shared decision making. The initial participation rate was 86% 
(n=390). Of the 390 women, 22 (6%) dropped out between baseline and disclosure of 
the test result; 11 affected and 11 unaffected. Of these 22 women, 5 withdrew for 
emotional reasons related to the informative decision aid (4 affected and 1 unaffected). 
All baseline analyses are on the remaining 368 women; 192 were affected and 176 
were unaffected. Of the 192 affected women, 23 received a positive test result (20 
BRCA1, 3 BRCA2). Of the 176 unaffected, 68 received a positive test result (47 
BRCA1, 21 BRCA2). Within the subgroup of mutation carriers, all 23 affected women 
were followed up, but 2 of the 68 unaffected women (3%; 1 BRCA1 and 1 BRCA2) 
withdrew because of high distress caused by the test result. 
 
Baseline variables 
Table 1 presents the sociodemographics and medical history of the affected and 
unaffected women both within the total sample and the subsample of mutation carriers. 
Within the total sample, several differences between affected and unaffected women 
were found:  (1) affected women were older (t = 7.62; P < 0.001), (2) had children 
more often (2 = 13.90; P < 0.001), (3) wanted (more) children less often (2 = 37.99; 
P < 0.001), (4) were religiously affiliated more often (2 = 8.01; P < 0.01), (5) had a 
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family history of breast cancer only more often (2 = 71.44; P < 0.001), (6) were an 
index case more often (2 = 264.91; P < 0.001), and (7) had first degree relatives who 
had died of cancer less often (2 = 8.59; P < 0.01). Within the subsample of mutation 
carriers, similar differences were found in 1, 3, 5, and 6, but not in 2, 4, and 7. 
 
Table 1. Baseline variables for the total sample and the subsample of mutation carriers per group (affected and 
unaffected) 
 Total Mutation carriers 
 Affected  
(n = 192) 
Unaffected 
(n = 176) 
Affected 
(n = 23) 
Unaffected 
(n = 66) 
Sociodemographics     
    Age: mean (SD) 47.4 (9.8)* 39.4 (10.4)* 44.9 (6.2)* 37.6 (10.3)* 
    Currently married/partner (%) 83  86 83  86 
    College or higher (%) 25  24 35  24 
    Employed (%) 62  68 70  70 
    Have children (%)  89*   74* 83  68 
    Want (more) children (%)    4*   28*    0*   33* 
    Religiously affiliated (%)  71*   57* 63  62 
Medical history     
   Personal medical history of bc/oc     
      No cancer (%) --- 100 --- 100 
      Breast cancer only (%) 90 --- 100 --- 
      Ovarian cancer only (%)   8 ---    0 --- 
      Breast and ovarian cancer (%)   2 ---    0 --- 
   Family medical history of bc/oc     
      Breast cancer only (%)   74*   27*  59*  12* 
      Ovarian cancer only  (%)     2*    5*    0*    4* 
      Breast and ovarian cancer (%)   24*   68*  41*  84* 
      Time since cancer diagnosis: mean (SD) 4.7 (5.9) --- 5.2 (5.9) --- 
      Index case   95*   11*   78*    4* 
      First degree relatives with bc/oc (%)  57  66  70 65 
      First degree relatives died of bc/oc (%)   24*   38*  35 33 
bc, breast cancer; oc, ovarian cancer.  
* Significant difference (P  0.05) between affected and unaffected women (independent t-test, 2-test). 
 
Well-being 
Table 2 presents the mean scores on well-being and the results of the independent t-
tests for affected versus unaffected women in the total sample at baseline. Affected 
women had higher scores on depression and cancer related distress, and a lower score 
on general health. The fifth column of Table 3 presents the mean scores on well-being 
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for affected and unaffected women in the subsample of mutation carriers at follow-up; 
the results of the independent t-tests are not presented. No differences were found for 
any of the well-being outcomes, although affected women tended to score higher on 
anxiety (t = 1.82, P = 0.07).  
 
Table 2. Mean scores (SD) on the outcome variables and independent t-tests for affected versus unaffected 
women in the total sample at baseline 
 Affected Unaffected  
 N Mean (SD) N Mean (SD) t P 
Well-being       
     Anxiety (STAI-state) 187 40.6 (11.0) 176 38.8 (11.2)  1.50   0.14 
     Depression (CESD) 191  10.0 (8.6) 176 7.6 (8.0)  2.81   0.01 
     Cancer related distress (IES) 187 20.7 (15.0) 176 17.4 (13.0)  2.20   0.03 
     General health 192 7.3 (1.6) 174 7.6 (1.5) -2.10   0.04 
Decision making       
     Valuation of PM 167 5.6 (2.4) 173  4.4 (2.6)  4.48 < 0.001 
     Valuation of BS 170 7.1 (2.4) 174  7.7 (2.3) -2.20   0.03 
     Valuation of PO 168 7.1 (2.2) 170  6.5 (2.7)  2.14   0.03 
     Valuation of OS 168 6.2 (2.7) 169  6.1 (3.0)  0.17   0.86 
     Strength of treatment preference  148 2.5 (1.1) 165  2.7 (1.1) -1.54   0.13 
     Decision uncertainty 167 2.9 (1.1) 173  2.6 (1.1)  1.85   0.07 
     Preference for decision making 158 3.5 (0.6) 172  3.8 (0.6) -3.57 < 0.01 
PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer 
screening. 
 
The last three columns of Table 3 present the results of the repeated measures analysis 
of variance; no main effect of cancer history (affected versus unaffected), a main effect 
of time (impact of a positive test result), and no interaction of cancer history and time 
was found for all outcomes. So both affected and unaffected women reported an 
increase in anxiety, depression, and cancer related distress, and a decrease in general 
health over time. Although the interactions of cancer history and time were not 
significant, the positive test result tended to have a greater impact on anxiety and 
cancer related distress in affected women. 
 
 
 
 
 
 
 
 49 
Table 3. Mean scores (SD) on the outcome variables (at baseline and at follow-up) and repeated measures 
analysis of variance for affected versus unaffected women in the subsample of mutation carriers 
   Mean (SD) Test of overall trend 
  N Baseline Follow-up Effect F P 
Well-being        
     Anxiety (STAI-state) affected 23 40.4 (11.5) 44.7 (11.1) Ca   1.98   0.16 
 unaffected 64 38.5 (10.9) 39.3 (12.7) Time   5.24   0.03 
     Interact   2.48   0.12 
     Depression (CESD) affected 23  8.7 (8.3)  12.7  (8.7) Ca   0.87   0.35 
 unaffected 63  7.9 (7.8)    9.7 (10.7) Time 10.22 <0.01 
     Interact   1.59   0.21 
     Cancer related distress (IES) affected 22 17.6 (13.1) 25.2 (12.3) Ca   0.50   0.48 
 unaffected 64 17.9 (13.3) 20.5 (15.4) Time 12.55 <0.01 
     Interact   3.00   0.09 
     General health  affected 22  7.8 (1.3)  7.1 (1.5) Ca   0.77   0.38 
 unaffected 60  8.0 (1.6)  7.6 (1.9) Time   6.77   0.01 
     Interact   0.70   0.41 
Decision making        
     Valuation of PM affected 21  5.3 (2.4)    6.7 (2.3)* Ca   6.13   0.02 
 unaffected 64  4.3 (2.7)    4.8 (2.6)* Time 13.18 <0.001 
      Interact   2.72   0.10 
     Valuation of BS affected 21  7.0 (1.8)  6.0 (2.2) Ca   5.02   0.03 
 unaffected 64  8.0 (2.1)  7.0 (2.3) Time 15.82 <0.001 
      Interact   0.00   0.98 
     Valuation of PO affected 20  6.8 (2.3)  7.6 (2.3) Ca   1.86   0.18 
 unaffected 60  6.0 (2.9)  6.7 (2.7) Time   7.58   0.01 
     Interact   0.10   0.75 
     Valuation of OS affected 20  5.7 (2.6)  4.7 (2.5) Ca   2.13   0.15 
 unaffected 60  6.7 (2.9)  5.7 (2.9) Time 12.05 <0.01 
     Interact   0.00   0.98 
     Strength of treatment pref. affected 19  2.4 (1.1)  3.3 (0.6) Ca   0.00   0.98 
 unaffected 58  2.8 (1.1)  2.9 (0.9) Time   9.80 <0.01 
     Interact   7.89   0.01 
     Decision uncertainty  affected 21  2.8 (1.1)  2.2 (1.0) Ca   0.42   0.52 
 unaffected 61  2.6 (1.1)  2.2 (1.0) Time 12.38 <0.01 
     Interact   0.37   0.55 
     Preference for DM affected 20  3.5 (0.6)  3.7 (0.8) Ca   1.12   0.29 
 unaffected 61  3.7 (0.6)  3.8 (0.7) Time   1.51   0.22 
     Interact   0.49   0.49 
Ca, cancer history; Interact, interaction between cancer history and time; PM, prophylactic mastectomy; BS, 
breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer screening; DM, decision making.  
* Significant difference (P  0.05) between affected and unaffected women at follow-up (independent t-test). 
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Well-being and time since diagnosis 
Table 4 presents the mean scores on well-being and the results of the independent t-
tests for affected women diagnosed with cancer  1 year previously versus those 
diagnosed > 1 year at baseline. Affected women diagnosed  1 year scored higher on 
anxiety, depression, and cancer related distress. In fact, affected women diagnosed > 1 
year and unaffected women had similar baseline scores, as can be seen by comparing 
Table 2 column 5 with Table 4 column 5.  
The fifth column of Table 5 presents the mean scores on well-being for affected 
women diagnosed  1 year and > 1 year in the subsample of mutation carriers at 
follow-up; the results of the independent t-tests are not presented. Affected women 
diagnosed  1 year scored higher on anxiety (t = 2.06, P = 0.05) and cancer related 
distress (t = 2.11, P = 0.05). Again, affected women diagnosed > 1 year and unaffected 
women had similar follow-up scores as can be seen by comparing Table 3 column 5 
with Table 5 column 5. 
The last three column of Table 5 present the results of the repeated measures 
analysis of variance; no interaction of time since diagnosis ( 1 year versus > 1 year) 
and time (impact of a positive test result) was found for any of the outcomes.    
 
Table 4. Mean scores (SD) on well-being and independent t-tests for affected women diagnosed  1 year versus 
> 1 year at baseline 
 Diagnosed  1 year Diagnosed > 1 year  
 N Mean (SD) N Mean (SD) t P 
Well-being at baseline       
     Anxiety (STAI-state) 91   42.4 (10.9) 93   38.9 (11.0)   2.14 0.03 
     Depression (CESD) 92 11.4 (8.3) 96   8.7 (8.6)   2.20 0.03 
     Cancer related distress (IES) 91   23.2 (15.2) 93   18.8 (14.5)   1.99 0.05 
     General health 92   7.1 (1.6) 97   7.4 (1.6) -1.18 0.24 
 
Treatment choice 
At baseline, within the total sample, more affected than unaffected women intended to 
obtain prophylactic mastectomy (χ2 = 8.86; P < 0.01); no difference was found for the 
treatment choice related to the ovaries (χ2 = 0.42; P = 0.52). At follow-up, within the 
subsample of mutation carriers, more affected than unaffected women intended to 
obtain prophylactic oophorectomy (χ2 = 3.96; P = 0.05); no difference was found for 
the treatment choice related to the breasts (χ2 = 1.58; P = 0.21). 
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Table 6 presents the intended treatment choice related to the breasts and ovaries for 
affected and unaffected mutation carriers, at baseline and at follow-up. At follow-up, 
all affected women had made a treatment choice while some unaffected women were 
still undecided. From baseline to follow-up, most mutation carriers did not change their 
intended treatment choice.  
 
Table 5. Mean scores (SD) on well-being (at baseline and at follow-up) and repeated measures analysis of 
variance for affected women diagnosed  1 versus > 1 year in the subsample of mutation carriers 
   Mean (SD) Test of overall trend 
  N Baseline Follow-up Effect F P 
Well-being        
     Anxiety (STAI-state)  1 year 11  45.5 (12.5) 49.4 (11.2)* t.s.d. 6.02 0.02 
 > 1 year 12 35.8 (8.7) 40.5 (9.5)* Time 3.65 0.07 
     Interact 0.03 0.87 
     Depression (CESD)  1 year 11 11.9 (8.3) 15.0 (7.7) t.s.d 2.81 0.11 
 > 1 year 12   5.7 (7.5) 10.7 (9.4) Time 8.59 0.01 
     Interact 0.48 0.50 
     Cancer related distress (IES)  1 year 11 22.5 (12.4) 30.4 (11.7)* t.s.d 5.53 0.03 
 > 1 year 11 12.7 (12.5) 20.1 (11.2)* Time 7.78 0.01 
     Interact 0.01 0.92 
     General health   1 year 11   7.4 (1.4)   6.8 (1.7) t.s.d 3.29 0.09 
 > 1 year 11   8.3 (0.9)   7.5 (1.1) Time 3.28 0.09 
     Interact 0.13 0.72 
t.s.d., time since diagnosis; Interact, interaction between time since diagnosis and time.  
* Significant difference (P  0.05) between affected women diagnosed  1 year and > 1 year at follow-up.  
 
Decision making 
Table 2 presents the mean scores on the decision making outcomes and the results of 
the independent t-tests for affected versus unaffected women in the total sample at 
baseline. Affected women had higher valuations for prophylactic mastectomy and 
oophorectomy, and a lower valuation for breast cancer screening. Furthermore, 
affected women had a lower preference for decision making, and tended to report a 
higher decision uncertainty.  
 The fifth column of Table 3 presents the mean scores on the decision making 
outcomes for affected and unaffected women in the subsample of mutation carriers at 
follow-up; the results of the independent t-tests are not presented. Affected women had 
a higher valuation for prophylactic mastectomy (t = 2.98; P  0.01). No differences 
were found for the other decision making outcomes. 
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The last three columns of Table 3 present the results of the repeated measures analysis 
of variance. A main effect of cancer history (affected versus unaffected) was found for 
the valuation of prophylactic mastectomy and breast cancer screening; affected women 
had a higher valuation for prophylactic mastectomy and a lower valuation for breast 
cancer screening. Also, a main effect of time (impact of a positive test result) was 
found for all decision making outcomes except the preference for decision making; 
both affected and unaffected women reported a higher valuation for prophylactic 
surgery, a lower valuation for screening, an increase in strength of treatment 
preference, and a decrease in decision uncertainty over time. Finally, an interaction 
effect of cancer history and time was found for strength of treatment preference; 
strength of treatment preference increased stronger over time for affected women. 
 
Table 6. Treatment intentions at baseline and at follow up for affected and unaffected mutation carriers 
   Follow-up intentions breasts 
   PM BS ? Total 
Affected Baseline intentions breasts PM   7   2 -   9 
  BS   1   9 - 10 
  ?   1   1 -   2 
  Total   9 12 - 21 
Unaffected  PM 12   3 1 16 
  BS   4 37 1 42 
  ?   2   3 1   6 
  Total 18 43 3 64 
   Follow-up intentions ovaries 
   PO OS ? Total 
Affected Baseline intentions ovaries  PO 12 - - 12 
  OS   1   2 -   3 
  ?   5   1 -   6 
  Total 18   3 - 21 
Unaffected  PO 28   6 1 35 
  OS   8 11 2 21 
  ?   2   1 2   5 
  Total 38 18 5 61 
PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer 
screening; ?, undecided. 
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DISCUSSION 
 
Summary of results 
This study is the first to show that general (STAI-state, CES-D) and cancer related 
distress (IES) increase when assessed 2 weeks after disclosure of a positive BRCA1 or 
BRCA2 test result in a relatively large sample of mutation carriers. The sample size 
enabled us to assess the differential impact on affected opposed to unaffected women. 
We found that both groups showed a similar increase on these outcomes, with a hint 
towards a more profound impact on affected women. We also found that affected 
women diagnosed ≤ 1 year previously reported an elevated general and cancer specific 
distress compared to women diagnosed > 1 year both at baseline and at follow-up. 
With respect to treatment choice, more affected women intended to obtain prophylactic 
surgery and valued it higher at both time points. With respect to the other decision 
making outcomes, affected women had a lower preference for decision making at 
baseline; no differences were found at follow-up. At follow-up, both affected and 
unaffected women showed an increase in strength of treatment preference and a 
decrease in decision uncertainty.  
 
Well-being 
Previous studies evaluating the impact of genetic testing and a positive test result, 
showed low levels of general and cancer related distress [7-13]. Also in our study, 
mean levels of anxiety, depression, and cancer related distress were below clinically 
significant levels. Women who had received a positive test result reported a significant 
increase in anxiety, depression, and cancer related distress. Although this seems 
logical, most previous studies showed no increased distress in mutation carriers 
[7,8,10,13]. Only one study [12] found a non-significant trend towards an increase in 
distress. This study included a small sample size of affected mutation carriers (n = 10). 
Earlier studies [7,8], with 53 and 25 mutation carriers respectively, did not show an 
increase in distress. However, they included both men and women who were aware 
that a BRCA1/2 mutation was segregating in their family, and who had been 
participating in genetic studies for a long time. This highly selected sample may not be 
representative for a clinic-based population. However, two other clinic-based studies 
also did not find an increase in distress [10,13]. One study [10] included a small 
sample of unaffected mutation carriers only (n = 25). The other study [13] included a 
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larger sample of both affected index cases (n = 43) and their unaffected relatives (n = 
35), but their follow-up assessment was 6 months after disclosure of the test result 
whereas ours was after 2 weeks. Therefore, it is conceivable that either a small sample 
size or a long interval between test result and assessment, have masked the short-term 
negative effects on general and cancer related distress in mutation carriers in previous 
studies. The point in time at which our follow-up questionnaire was filled out may 
have contributed to our finding of an increase in distress; it is unlikely that 
psychological reactions are fully balanced and that adaptation is complete so shortly 
after learning their carrier status. Possibly, a positive test result causes transient distress 
on the short term only.  
 
Differential well-being in affected versus unaffected women 
Affected women scored higher on depression and cancer related distress and lower on 
general health at baseline, and tended to score higher on anxiety at follow-up. We 
assume that having a cancer history and especially a short time since cancer diagnosis 
explained the increased distress in affected women. Indeed, we found that affected 
women diagnosed ≤ 1 year previously had higher distress levels as those diagnosed > 1 
year, who scored almost identical as unaffected women. This was also found in a 
previous study [12].  
Other confounding variables, such as being an index case (meaning that usually 
more time is needed for DNA-analysis and facing the task of informing their family 
after a positive test result) or older age, are also candidates for explaining the worse 
well-being of affected women at baseline. However, they could be ruled out as 
explanation because in a previous study [20] was found that levels of distress in 
affected women did not depend on whether or not genetic testing was initiated. We 
checked whether older age was associated with an increased distress level, but this was 
not the case (data not shown).  
Furthermore, affected women tended to experience a stronger increase in 
anxiety and cancer related distress after a positive test result when compared to 
unaffected women; within the group of affected women, this was independent of time 
since diagnosis. We can only speculate about the cause of this greater emotional 
reactivity. A plausible explanation might be that affected women are additionally 
distressed as a consequence of a reactivation of negative feelings related to their 
previous cancer diagnosis and treatment; they do not only have to cope with their 
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carrier status, but also to re-evaluate their disease in the light of this new information. 
Other explanations are suggested by previous studies; one indicated that affected index 
cases experienced difficulties in transmitting their results to families [21], and another 
suggested that affected women reported more distress after a positive test result 
because they had underestimated its impact [22]. 
 
Associations between decision uncertainty and well-being 
Well-being is expected to be worse in women who feel more uncertain about which 
treatment to choose. Indeed, after disclosure of a positive test result, we found that a 
worse well-being was associated with a higher decision uncertainty; the correlations of 
decision uncertainty with anxiety, depression, cancer related distress, and general 
health were 0.34 (P = 0.00), 0.28 (P = 0.01), 0.39 (P = 0.00), and -0.30 (P = 0.01), 
respectively. At baseline, however, when the treatment choice is still hypothetical, no 
such association were found (data not shown). These findings underline the impact of 
the decision making process on well-being after a positive test result.    
Surprisingly, we found that over time, a worse well-being was concomitant with 
a lower decision uncertainty (see Table 3). Several explanations could be given. 
Possibly, women may be more certain about their treatment choice, simply because 
they are certain about their carriers status. Another explanation is that mutation 
carriers, who feel more certain about their choice, also have a stronger feeling that they 
have no choice and therefore experience a loss in well-being. Furthermore, women 
might bolster their decision to cope with the distress caused by a positive test result; in 
other words, fear and distress may induce a wish to act firmly. 
 
Limitations 
Several limitations should be considered. First, the sample of mutation carriers is 
relatively small. Nevertheless, it is the greatest consecutive clinic-based sample of 
mutation carriers to date to study differences between affected and unaffected women. 
Because we included a consecutive sample, heterogeneity exists in our sample. Not all 
affected women were an index case, some were members of a family in which a 
mutation was found before. And not all unaffected women were part of a family with a 
known mutation, some were index cases themselves. Second, all of our mutation 
carriers had received an informative decision aid. Thus, it could be argued that changes 
in well-being, treatment choice, and decision making outcomes were a result of the 
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informative decision aid and not of disclosure of a positive test result. However, the 
informative decision aid did not affect well-being, strength of treatment preference, 
decision uncertainty, and preference for decision making, although it did lead to more 
considerations towards prophylactic surgery and higher valuations for prophylactic 
surgery and lower valuations for screening [14]. Therefore, it is reasonable to attribute 
the impact of a positive test result on well-being, strength of treatment preference, and 
decision uncertainty, to disclosure of a positive test result and not to the informative 
decision aid. Third, long term follow-up was not obtained because in the second part of 
our study, mutation carriers will be randomized to a second decision aid, consisting of 
value assessment and individualized treatment information derived from a decision 
model [23], or to the control group. The follow-up time point reported here, will be the 
baseline assessment for this second intervention. 
 
Clinical recommendations 
In the Netherlands, protocols for psychosocial care in genetic counseling for a possible 
BRCA1/2 mutation are often based on previous experience from predictive testing for 
Huntington disease [24]. A very important difference with a hereditary breast/ovarian 
cancer syndrome is that it is not possible to prevent Huntington disease or to detect it 
in an early curable stage. Furthermore, there exists no sporadic form of the disease; 
people affected by Huntington disease always carry the mutation. Finally, Huntington 
disease is always fatal. Consequently, there is no group of affected mutation carriers 
for whom DNA-diagnosis implicates a substantial change in prognosis or probability to 
develop a new serious disease. In contrast to this situation, the large majority of breast 
cancers is sporadic and relatives of sporadic breast cancer patients usually only face a 
minor increase in breast cancer risk. Diagnosing a BRCA1/2 mutation in a breast 
cancer patient implicates a large probability of developing a second primary breast 
cancer and/or ovarian cancer. Until now, protocols for psychosocial care in genetic 
counseling for a possible BRCA1/2 mutation have been mainly tailored towards 
unaffected women, analogous to the protocol for Huntington disease [24]. Our results 
indicate that this may not be justified. Affected women, especially those who have 
been recently diagnosed with cancer, may need more support than unaffected women. 
We suggest to follow this group more closely and to stimulate contact with a 
psychosocial worker for support. Our research does not permit us to give specific 
recommendations about the form of these interventions but this should be the topic of 
further research. 
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ABSTRACT 
 
The aim of the study was to evaluate the impact of a decision aid (DA) and its timing 
in women being tested for a BRCA1/2 mutation. Women with and without a previous 
history of cancer were included after blood sampling for genetic testing. The DA 
consisted of a brochure and video providing information on screening and prophylactic 
surgery. To evaluate the impact of the DA, women were randomised to the DA group 
(n = 184), receiving the DA 2 weeks after blood sampling, or to the control group (n = 
184). To evaluate the impact of timing, mutation carriers who had received the DA 
before the test result (n = 47) were compared to mutation carriers who received the DA 
after the test result (n = 42). Data were collected on well-being, treatment choice, 
decision and information related outcomes. The impact of the DA was measured 4 
weeks after blood sampling. The impact of timing was measured 2 weeks after a 
positive test result. The DA had no impact on well-being. Regarding decision related 
outcomes, the DA group more frequently considered prophylactic surgery (P = 0.02) 
corroborated with higher valuations (P = 0.04). No differences were found for the 
other decision related outcomes. Regarding information related outcomes, the DA 
group felt better informed (P = 0.00), was more satisfied with the information (P = 
0.00), and showed more accurate risk perceptions. Timing of the DA had no effect on 
any of the outcomes. No interactions were found between the DA and history of 
cancer. In conclusion, women being tested for a BRCA1/2 mutation benefit from the 
DA on information related outcomes. Because timing had no effect, the DA is 
considered useful either before or after the test result.  
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INTRODUCTION 
 
The discovery of the BRCA1 and BRCA2 genes has induced widespread interest in 
genetic testing for inherited susceptibility of breast and ovarian cancer [1,2]. Women 
with a BRCA1/2 mutation have a high lifetime risk for breast cancer (56 - 85%) and/or 
ovarian cancer (16 - 63%) [3,4]. They currently face the difficult choice between 
screening and prophylactic surgery [5].  
An important reason to ask for genetic testing is to obtain certainty about the 
need for screening and/or prophylactic surgery [6-8]. These treatment options have 
different risk - benefit profiles that women may value differently. The decision about 
optimal treatment depends on women’s personal values for the health states after each 
of the treatment options [9]. In order to choose between screening and prophylactic 
surgery in a way that reflects their personal values, these women need to be prepared 
for decision making by providing information on the treatment options and their risks 
and benefits.  
Decision aids (DAs) are interventions designed to help people make specific 
and deliberative choices among options by providing information on the options and 
outcomes relevant to a person’s health status [10]. Decision aids have been found to be 
feasible and acceptable to patients and to increase the agreement between patients’ 
values and decisions [11]. A recent systematic review found that DAs improve 
patients’ knowledge and realistic expectations of treatment options, reduce decisional 
conflict, and stimulate patients to play a more active role in decision making [10]. 
Decision aids appeared to have a variable effect on treatment choice, and little effect 
on anxiety, satisfaction with the decision making process and the decision [10]. The 
impact on other outcome measures, such as health outcomes and persistence with 
treatment choice, remains uncertain [10]. 
Decision aids in the context of genetic counselling for women already decided 
to undergo genetic testing for a BRCA1/2 mutation is a new development. There is 
discussion about the timing of informing women about the treatment options. Some 
believe that this information should be withheld until after a positive test result in order 
to prevent unnecessary burden. Others believe that this information should be given 
earlier to achieve full disclosure of the consequences of a positive test result. 
Therefore, we investigated the impact of a DA on a broad range of outcomes and also 
whether the time point of presenting information mattered. The DA consisted of a 
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brochure and video to be viewed at home, providing information on screening and 
prophylactic surgery, and the physical, emotional, and social consequences. The 
present study is part of a larger shared decision making study in which the impact of 
another DA, including trade-offs and a formal treatment advice derived from a 
decision model [9], will be evaluated. 
 
MATERIALS AND METHODS 
 
Participants 
We included women with and without a personal history of breast or ovarian cancer, 
who provided a blood sample for BRCA1/2 testing at the Family Cancer Clinics of the 
University Hospitals of Nijmegen (accrual started March 1999), Groningen (accrual 
started June 1999), and Maastricht (accrual started January 2000). These clinics cover 
the population of the eastern part of the Netherlands. The closing date for inclusion 
was November 2001. Women were excluded if they had a cognitive disorder that 
precluded informed consent, had insufficient knowledge of the Dutch language, were 
diagnosed with distant metastases, had undergone both bilateral mastectomy and 
oophorectomy, or had been treated with chemotherapy, radiotherapy, or surgery for 
breast or ovarian cancer less than 1 month before blood sampling. The study was 
approved by the local research ethics committees. 
 
Intervention  
The DA consisted of a brochure and video. Unlike usual information material, our 
information concentrated on contrasting treatment options. The 14-page brochure 
presented detailed information on treatment options available in 1998 in the 
Netherlands, and on the physical, emotional, and social consequences in qualitative 
terms, but whenever possible in quantitative terms (see summary of brochure and 
references in Appendix). In the 45 minutes video, we dealt with the consequences of 
the treatment options through interviews with eight mutation carriers, with and without 
a previous history of cancer, who had chosen for either screening or prophylactic 
surgery. In addition, these women described how they went through the decision 
making process. Shots of the results of prophylactic mastectomy with and without a 
reconstruction were shown. The DA was viewed at home. A short evaluation form was 
sent with the DA. The video and the evaluation form were to be returned after 1 week. 
 63 
The DA was developed in close collaboration with the specialists involved in the 
Family Cancer Clinics. It was judged to be balanced in a pretest by the interviewed 
mutation carriers, the specialists, and the working group on familial cancer of the 
Dutch Society of Psychosocial Oncology.  
 
Standard procedure at the Family Cancer Clinics 
Genetic testing for a BRCA1/2 gene mutation is offered to women when the family 
history and the cancer risk estimate suggests a genetic predisposition. Before blood 
sampling, usually two counselling sessions of 1 hour with a geneticist or genetic 
counsellor take place wherein the family history is discussed, a family pedigree is 
made, and information is provided on genetic risk, psychosocial consequences of 
genetic testing, and briefly on the possible treatment options. If the woman decides to 
undergo genetic testing, a blood sample is obtained. If the mutation is known in the 
family, an appointment is made for disclosure of the test result after 6 - 12 weeks. 
Women without a known mutation in the family receive an invitation for an 
appointment after extensive molecular analyses, which may take several months.  
When a mutation is found, more detailed information is provided on the 
possible treatment options by a geneticist or genetic counsellor. A social worker or a 
psychologist is generally present when a positive test result is disclosed to women 
unaffected with cancer. Mutation carriers are offered additional consultations with a 
multidisciplinary team involved in the Family Cancer Clinic, generally consisting of a 
medical oncologist, gynaecologist, and surgeon. These appointments usually take place 
about 1 - 2 months after disclosure of a positive test result. 
 
Randomisation and blinding 
Randomisation of the DA took place by family (first-degree up to and including third-
degree relatives) to avoid contamination. Randomisation was computer generated in 
blocks of 10, and stratified by personal medical history of breast/ovarian cancer. 
Randomisation was performed after obtaining informed consent and the baseline 
assessment. Neither subjects nor members of the study staff were blinded to 
intervention assignment.  
 
Study procedure 
Eligible women were informed about the present study by the clinical geneticist or 
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genetic counsellor after blood sampling for genetic testing. Women were subsequently 
contacted by a research assistant to confirm eligibility and to inform them about the 
study. Women who gave verbal consent were enrolled and received an informative 
letter describing the study, a consent form, and the baseline questionnaire T1. Women, 
awaiting their test result, were randomly assigned to the DA group, who received the 
DA 2 weeks after blood sampling, or to the control group, who received no additional 
information (see Figure 1). At 4 weeks after blood sampling (T2), the impact of the 
DA was evaluated by comparing the DA group with the control group (see Figure 1). 
Women from the DA group who tested positive (i.e. a BRCA1 or BRCA2 mutation 
was found) had received the DA before the test result (DA_b), and women from the 
control group subsequently received the DA after the positive test result (DA_a). At 2 
weeks after a positive test result (T3), the impact of timing of the DA was assessed by 
comparing the DA_b group with the DA_a group (see Figure 1). Data were collected 
using questionnaires. 
 
MEASURES 
 
Baseline characteristics 
Data were obtained on sociodemographic (age, marital status, education level, 
employment status, presence of children, wanting (more) children, and being 
religiously affiliated) and medical background (personal and family history of 
breast/ovarian cancer, time since last cancer diagnosis, whether a mutation was known 
in the family, whether first-degree relatives had breast or ovarian cancer, and whether 
they died from breast or ovarian cancer). 
 
Well-being 
We collected data on anxiety (state scale of the Spielberger State - Trait Anxiety 
Inventory) [12], depression (Center for Epidemiologic Studies Depression Scale) [13], 
and cancer related distress (Impact of Event Scale) [14]. Furthermore, we asked 
women to rate their general health state during the last week on a 11-point scale 
ranging from 0 (very bad health state) to 10 (excellent health state). 
 
Treatment choice 
Treatment choice was asked for both breasts and ovaries. The treatment choice related 
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to breast cancer risk was between “prophylactic mastectomy”, “breast cancer 
screening”, and “undecided”. The treatment choice related to ovarian cancer risk was 
between “prophylactic oophorectomy”, “ovarian cancer screening”, and “undecided”. 
Valuations for the treatment options were asked on a 10-point scale ranging from 1 
(very bad) to 10 (excellent). 
 
Decision related outcomes 
The decision related outcomes were asked separately for the breasts and ovaries. An 
overall score was created by adding the scores for the decision related to breast and 
ovarian cancer risk and dividing this by the number of items included.  
Strength of treatment preference was asked on a 4-point Likert scale ranging 
from 1 (weak preference) to 4 (very strong preference). Those who filled out 
“undecided” as treatment choice were assigned a value of 0 (no preference).  
Decision uncertainty was measured with three items related to the uncertainty 
subscale of the Decisional Conflict Scale by O’Connor [15]. The items were: “I doubt 
what to choose”, “This decision is hard for me to make”, and “I am not sure what to 
choose”, measured on a 5-point scale ranging from 1 (very much disagree) to 5 (very 
much agree).  
Preference for decision making was measured with the two decision making 
items from the Problem-Solving Decision-Making Scale (PSDM) from Deber et al 
[16]. The items were: “Given the risks and benefits of the possible treatment options, 
who should decide how acceptable those risks and benefits are for you”, and “Given 
the risks and benefits of the possible treatment options, who should decide which 
treatment option should be selected”, measured on a 5-point scale ranging from 1 
(doctor alone) to 5 (I alone). 
 
Information related outcomes 
Subjective knowledge was measured by asking women to rate their knowledge for 
prophylactic mastectomy, breast cancer screening, breast self-examination, 
prophylactic oophorectomy, and ovarian cancer screening, on a 10-point scale ranging 
from 1 (very bad) to 10 (excellent). An overall score for subjective knowledge was 
created by adding the scores on the five items and dividing this by five.  
The amount of received information was measured on a 7-point scale ranging 
from 1 (I received way too little information), 4 (I received exactly enough 
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information), to 7 (I received way too much information), for the decision related to 
breast and ovarian cancer risk. An overall score was created by adding the scores and 
dividing this by two. 
Satisfaction with quality of information was measured with a 13-item 
questionnaire on a 6-point scale ranging from 1 (not satisfied), 4 (rather satisfied), to 6 
(very much satisfied). Women were offered a series of items regarding cancer risks, 
efficacy of treatment options, and physical, emotional, and social consequences. An 
overall score was created by adding the scores on the 13 items and dividing this by 13.  
Risk perception was asked for the following eight items (the range that we 
considered accurate for subsequent analyses is given in parentheses): breast (8 - 14%) 
and ovarian cancer risk (1 - 3%) in the general female population, breast (60 - 85%) 
and ovarian cancer risk (15 - 60%) in BRCA1/2 mutation carriers, the possibility of 
cure when breast (65 - 80%) and ovarian cancer (35 - 50%) is detected during 
screening in BRCA1/2 mutation carriers, and residual risk after prophylactic surgery of 
breasts (3 - 12%) and ovaries (3 - 12%) in mutation carriers. Women were asked to 
give a risk estimate in a range from 0 to 100%. For each item, a new variable was 
created classifying the risk estimate as underestimate, accurate, or overestimate. In the 
analyses, risk accuracy was dichotomised in accurate and inaccurate.   
We did not assess the amount of received information, satisfaction with quality 
of information, and risk perception at baseline to avoid information-seeking behaviour 
in the control group, thus making the control group less representative. 
 
Sample size 
To detect a difference of at least 10% in the decision uncertainty score between the DA 
and control groups, with a 5% two-sided significance level and a power of 80%, we 
needed a sample size of 180 women in each group.  
 
Statistical analyses 
We analysed data from women who completed the questionnaire at baseline and at the 
time point of interest on an intention to treat basis. In multi-item scales with missing 
data, scale values were calculated if at least half of the items were filled out by 
imputing the mean of the remaining items. We compared the intervention groups at 
baseline using 2 tests for categorical variables, and t-tests for continuous variables. To 
evaluate the impact of the DA, we compared the DA group with the control group at 
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T2 (see Figure 1). To evaluate the impact of timing of the DA, we compared the DA_b 
group with the DA_a group at T3 (see Figure 1). For continuous variables, 
comparisons between intervention groups were made using analyses of covariance 
(ANCOVA) [17]. The baseline assessment of the outcome measure, when present, was 
included as a covariate. Baseline characteristics tabulated in Table 1, which differed 
between the intervention groups (P < 0.10), were also included as covariate. Effect 
sizes (d) were calculated as the adjusted mean of the DA group minus the adjusted 
mean of the control group, and as the adjusted mean of the DA_b minus the adjusted 
mean of the DA_a group, divided by the standard deviation of the difference score. For 
two categorical variables, namely “treatment choice” and “accuracy of risk 
perception”, comparisons between groups were done using 2 tests. We used a P level 
of 0.05 to indicate statistical significance. The number of subjects providing data for 
the various analyses varied due to missing data.  
Because randomisation took place by family, and because family members were 
not independent on the outcome measures, statistical significance will be inflated when 
all women are treated as independent units. At baseline, we included 33 families with 
multiple participating members (range 2 - 5), with a total of 80 women. The subsample 
of mutation carriers consisted of 10 families with multiple members (range 2 - 3), with 
a total of 23 women. To counter inflation, we further examined significant effects by 
incorporating only the first included family member in the analyses. 
In a previous study of ours, we found that after blood sampling for genetic 
testing, women affected with breast or ovarian cancer reported a worse well-being and 
a lower preference for participation in decision making than women without a previous 
history of cancer [18]. To explore a possible differential impact of the DA in women 
with and without a history of cancer, we examined interactions between the DA (and 
its timing) and history of cancer using the ANCOVA.   
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Figure 1.  Participant flow  
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RESULTS 
 
Participants 
The participant flow is presented in Figure 1. During the study period, 510 women 
were ascertained of whom 453 (89%) were eligible. Of these 453 women, 390 (86%) 
gave informed consent. At T1, six (2%) women withdrew. Of the remaining 384 
women, 194 were randomised to the DA group and 190 to the control group. Of the 
194 women from the DA group, six (3%) withdrew; four indicated an emotional 
burden related to being informed, one indicated that she did not want to fill out any 
more questionnaires for emotional reasons, and one indicated that the study was too 
time consuming. Of the remaining 188 women from the DA group, four (2%) did not 
view the DA because of an emotional burden. These four women remained in the study 
and were analysed on an intention to treat basis. At T2, four (2%) women withdrew in 
the DA group and six (3%) in the control group. In both groups, none of the women 
declined to receive their test result. In the DA group, 47 (26%) women received a 
positive test result (38 BRCA1, nine BRCA2). In the control group, 44 (24%) women 
received a positive test result (29 BRCA1, 15 BRCA2). Mutation carriers from the DA 
group had received the DA before the test result (DA_b). Mutation carriers from the 
control group subsequently received the DA after the test result (DA_a). Of the 44 
women from the DA_a group, two (5%) withdrew because of high emotional distress 
caused by the test result; it is unclear whether their withdrawal was also related to the 
DA. Of the remaining 42 women from the DA_a group, all viewed the DA. At T3, 
none of the women withdrew.  
 
Baseline characteristics 
Table 1 presents the sociodemographic and medical background, and the baseline 
assessment of well-being. Between the DA and control groups, significant differences 
were found for being religiously affiliated, anxiety, and general health. Between the 
mutation carriers in the DA_b and DA_a group, a significant difference was found for 
being religiously affiliated.  
 
Evaluation of the decision aid 
The DA was viewed once by 49%, and twice or more by 51%. Most respondents 
(82%) found that it contained exactly enough information, and 13% stated that it 
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contained slightly too little information. In all, 56% reported no negative, 31% a 
scarcely negative, 12% a rather negative, and 1% a negative emotional reaction 
towards the information provided. The evaluation forms contained predominantly 
positive remarks.  
 
Table 1. Baseline characteristics by intervention group  
 DA 
(n = 184) 
Control 
(n = 184) 
DA_b 
(n = 47) 
DA_a 
(n = 42) 
Sociodemographic background     
     Age: mean (SD) 43.7 (11.3) 43.5 (10.4) 38.7 (10.0) 40.3 (9.9) 
     Currently married/partner (%)  84  85 85  86 
     College or higher (%)  37  32 30  43 
     Employed (%)  65  65 70  69 
     Have children (%)  80  83 75  69 
     Want (more) children (%)  17  15 22  28 
     Being religiously affiliated (%)   57*   71*   52†   74† 
Personal medical history     
     No cancer (%) 46 49 70 76 
     Breast cancer only (%) 49 46 30 24 
     Ovarian cancer only (%)   4   4   0   0 
     Breast and ovarian cancer (%)   1   1   0  0 
Family medical history     
     Breast cancer only (%) 47 54 27 20 
     Ovarian cancer only  (%)   3   3   0   3 
     Breast and ovarian cancer (%) 50 43 73 77 
     Known familial mutation (%) 47 44 77 76 
     First degree relatives with bc/oc (%) 66 69 71 77 
     First degree relatives died of bc/oc (%) 28 27 34 31 
Well-being      
     Anxiety: mean (SD)   40.9 (11.4)*  38.6 (10.7)* 40.1 (10.6) 37.4 (11.5) 
     Depression: mean (SD) 9.3 (8.6) 8.4 (8.1) 7.5 (7.1) 8.6 (8.6) 
     Cancer related distress: mean (SD) 20.1 (14.8) 18.1 (13.5) 18.5 (13.8) 17.1 (12.9) 
     General health: mean (SD)     7.3 (1.7)*     7.6 (1.4)*     7.9 (1.4)     8.0 (1.5) 
bc, breast cancer; oc, ovarian cancer.  
* P < 0.10 comparing the DA and control groups. † P < 0.10 comparing the DA_b and DA_a groups. 
 
Impact of the decision aid 
 
Well-being.  
No significant differences were found between the DA and control groups for anxiety, 
depression, cancer related distress, and general health (Table 2).  
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Treatment choice  
At baseline (T1), no significant differences were found between the DA and control 
groups (Table 3). At T2, significant differences were found; women in the DA group 
more often chose for prophylactic surgery. For the valuation of the treatment options 
(Table 2), significant differences were found between the DA and control groups; 
women in the DA group gave a higher value for prophylactic surgery and a lower value 
for screening, corroborating our finding of more choices for prophylactic surgery. 
 
Decision related outcomes 
For strength of treatment preference, decision uncertainty, and preference for decision 
making (Table 2), no significant differences were found. 
 
Information related outcomes 
For subjective knowledge, amount of received information, and satisfaction with 
quality of information (Table 2), significant differences were found between the DA 
and control groups; women in the DA group felt better informed and were more 
satisfied with the amount and quality of the information.  
The mean risk estimates, the percentage under-, accurate, and overestimates, are 
presented in Table 5. Significant differences were found in risk accuracy for three of 
the eight items; the DA group made significantly more accurate risk estimates for 
BRCA1/2 related ovarian cancer risk, and cure of BRCA1/2 related breast cancer 
diagnosed during screening, and cure of BRCA1/2 related ovarian cancer diagnosed 
during screening.   
 
Impact of timing of the decision aid 
For well-being, decision and information related outcomes (Table 3), and treatment 
choice (Table 4) no significant differences were found between the mutation carriers in 
the DA_b and DA_a groups, with the exception that the DA_a group made significant 
more accurate risk estimates for cure of BRCA1/2 related ovarian cancer diagnosed 
during screening (Table 5). 
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Table 2. Impact of DA: unadjusted mean scores (SD), results and effect sizes (d) from the ANCOVA comparing 
the DA and C groups 
 Group n T1 T2 F P d 
Well-being         
     Anxiety (STAI-state) DA 176 41.0 (11.4) 40.4 (11.3)    
 C 174 38.3 (10.6) 37.3 (10.6)   1.90 0.17  0.10 
     Depression (CESD) DA 176  9.3 (8.6)  8.7 (8.9)    
 C 175  8.1 (7.6)  7.5 (7.3)   0.02 0.89  0.01 
     Cancer related distress (IES) DA 169 19.9 (14.7) 18.6 (15.0)    
 C 174 17.6 (13.1) 16.3 (14.2)   0.14 0.71  0.03 
     General health DA 173  7.3 (1.7)  7.4 (1.5)    
 C 172  7.7 (1.5)  7.6 (1.6)   0.25 0.62  0.04 
Decision related outcomes        
     Valuation of PM DA 164  5.1 (2.6)  5.6 (2.5)    
 C 160  4.8 (2.5)  5.0 (2.6)   4.41 0.04  0.17 
     Valuation of BS DA 165  7.2 (2.5)  6.5 (2.5)    
 C 162  7.5 (2.2)  7.4 (2.1) 14.86 0.00 -0.30 
     Valuation of PO DA 161  6.9 (2.3)  7.4 (2.2)    
 C 160  6.7 (2.6)  6.9 (2.5)   4.29 0.04  0.16 
     Valuation of OS DA 160  5.9 (2.8)  4.9 (2.5)    
 C 159  6.3 (2.9)  6.0 (2.7) 15.64 0.00 -0.31 
     Strength of treatment preference  DA 150  2.7 (1.1)  2.6 (1.0)    
 C 150  2.7 (1.1)  2.7 (1.0)   1.38 0.24 -0.10 
     Decision uncertainty DA 157  2.7 (1.1)  2.6 ( 0.9)    
 C 162  2.8 (1.1)  2.7 (1.0)   1.20 0.27 -0.09 
    Preference for decision making DA 155  3.7 (0.6)  3.8 (0.6)    
 C 159  3.5 (0.6)  3.7 (0.6)   1.46 0.23 -0.10 
Information related outcomes        
     Subjective knowledge DA 176  6.1 (1.5)  6.8 (1.3)    
 C 174  6.1 (1.5)  6.3 (1.4) 22.31 0.00  0.36 
     Amount of received information DA 171 *  3.2 (0.9)    
 C 166 *  2.5 (1.0) 50.37 0.00  0.54 
     Satisfaction quality information DA 176 *  3.8 (0.9)    
 C 171 *  3.2 (1.0) 28.48 0.00  0.40 
C, control; PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, 
ovarian cancer screening; * not measured at baseline (T1). 
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Table 3. Impact of timing of DA: unadjusted mean scores (SD), results and effect sizes (d) from the ANCOVA 
comparing the DA_b and the DA_a groups 
 Group n T1 T3 F P d 
Well-being         
     Anxiety (STAI-state) DA_b 45 40.3 (10.8) 40.9 (12.9)    
 DA_a 40 37.8 (11.5) 40.2 (12.4) 0.25 0.62 -0.08 
     Depression (CESD) DA_b 45  7.7 (7.2) 11.2 (11.0)    
 DA_a 39  8.6 (8.8)  9.4 (9.4) 2.42 0.12  0.24 
     Cancer related distress (IES) DA_b 44 18.4 (13.5) 22.6 (15.7)    
 DA_a 40 17.3 (13.1) 20.3 (13.9) 0.36 0.55  0.09 
     General health DA_b 43  7.8 (1.5)  7.4 (1.9)    
 DA_a 37  8.0 (1.5)  7.7 (1.7) 0.23 0.63 -0.08 
Decision related outcomes         
     Valuation of PM DA_b 44  5.0 (2.4)  5.6 (2.5)    
 DA_a 39  4.0 (2.4)  4.7 (2.7) 0.02 0.89  0.02 
     Valuation of BS DA_b 44  7.3 (2.4)  6.3 (2.3)    
 DA_a 39  8.2 (1.6)  7.4 (2.1) 1.16 0.29 -0.17 
     Valuation of PO DA_b 41  6.7 (2.7)  7.3 (2.6)    
 DA_a 38  5.8 (2.8)  6.5 (2.5) 0.09 0.77  0.05 
     Valuation of OS DA_b 41  5.6 (2.9)  4.7 (2.8)    
 DA_a 38  7.2 (2.5)  6.2 (2.8) 0.80 0.38 -0.14 
     Strength of treatment preference  DA_b 40  2.8 (1.2)  3.1 (0.8)    
 DA_a 36  2.6 (1.1)  2.8 (1.0) 0.64 0.43  0.13 
     Decision uncertainty DA_b 43  2.5 (1.1)  2.1 (0.9)    
 DA_a 38  2.7 (1.1)  2.4 (1.0) 0.29 0.59 -0.08 
    Preference for decision making DA_b 42  3.8 (0.6)  3.8 (0.7)    
 DA_a 37  3.5 (0.6)  3.6 (0.7) 0.17 0.69 -0.06 
Information related outcomes        
     Subjective knowledge DA_b 45  6.2 (1.8)  7.1 (1.3)    
 DA_a 40  6.1 (1.5)  6.8 (1.4) 0.83 0.37  0.14 
     Amount of received information DA_b 43 *  3.3 (0.9)    
 DA_a 40 *  3.3 (0.9) 0.25 0.62  0.08 
     Satisfaction quality information DA_b 45 *  3.9 (1.0)    
 DA_a 38 *  3.7 (0.9) 1.01 0.32  0.15 
PM, prophylactic mastectomy; BS, breast cancer screening; PO, prophylactic oophorectomy; OS, ovarian cancer 
screening; * not measured at baseline (T1). 
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Additional analyses incorporating only the first included family member  
Significant differences found above were further tested by including only the first 
family member. Differences between the DA and control groups were no longer 
significant for the valuation of prophylactic mastectomy (P = 0.13), the valuation of 
prophylactic oophorectomy (P = 0.15), and risk accuracy of BRCA1/2 related ovarian 
cancer risk (P = 0.18).  
 
Table 4. Treatment choice related to breast and ovarian cancer risk at T1 and T2 (for the DA and control groups) 
or T3 (for the DA_b and DA_a groups) 
 DA Control DA_b DA_a 
Treatment choice related to bc risk  at: T1 T1 
     Prophylactic mastectomy 61 (35)   53 (31) 17 (37)   8 (20) 
     Breast cancer screening 92 (53) 103 (60) 24 (52) 30 (73) 
     Undecided 20 (12) 15 (9)   5 (11) 3 (7) 
 χ2 = 1.89; P = 0.39 χ2 = 4.13; P = 0.13 
Treatment choice related to bc risk at: T2 T3 
     Prophylactic mastectomy 69 (41)   55 (32) 18 (40)   8 (21) 
     Breast cancer screening 80 (47) 104 (61) 26 (58) 29 (74) 
     Undecided 21 (12) 11 (7) 1 (2) 2 (5) 
 χ2 = 7.84; P = 0.02 χ2 = 3.94; P = 0.14 
Treatment choice related to oc risk at:  T1 T1 
     Prophylactic oophorectomy 112 (66) 105 (62) 27 (61) 21 (51) 
     Ovarian cancer screening   36 (21)   44 (26) 10 (23) 15 (37) 
     Undecided   21 (13)   20 (12)  7 (16)   5 (12) 
 χ 2 = 1.05; P = 0.59 χ2 = 1.98; P = 0.37 
Treatment choice related to oc risk at: T2 T3 
     Prophylactic oophorectomy 122 (73) 107 (63) 34 (81) 22 (56) 
     Ovarian cancer screening   24 (14)   48 (28)  6 (14) 14 (36) 
     Undecided   21 (13) 14 (8) 2 (5) 3 (8) 
 χ2 = 10.37; P = 0.01 χ2 = 5.87; P = 0.05 
bc, breast cancer; oc, ovarian cancer. Values are numbers (percentage) of women. 
 
Interaction between the decision aid (and its timing) and history of cancer 
No interactions were found between the DA and history of cancer. No interactions 
were found between timing of the DA and history of cancer, except for valuation of 
prophylactic mastectomy (P < 0.01) and breast cancer screening (P < 0.01). Women 
affected with cancer valued prophylactic mastectomy higher and breast cancer 
screening lower in the DA_a group compared to the DA_b group, whereas for women 
without a previous history this was in the opposite direction. 
 
 75 
Table 5. Mean risk perception (SD), percentage under- ( - ), accurate ( = ), and overestimates ( + ) by 
intervention group.  
  T2  T3 
 Group Mean (SD) -(%) =(%) +(%) Group Mean (SD) -(%) =(%) +(%) 
General           
     bc risk  DA 25.3 (17.4)   2 41 57 DA_b 20.4 (18.6)   9 56 35 
 C 27.0 (19.8)   3 38 59 DA_a 21.0 (18.8)   5 59 36 
     oc risk  DA 20.3 (17.9)   1 11 88 DA_b 16.4 (21.0)   2 24 74 
 C 21.1 (18.4)   2  7 91 DA_a 11.9 (12.8)   0 21 79 
BRCA1/2           
     bc risk  DA 65.2 (17.4) 40 57   3 DA_b 70.6 (14.7) 28 68   4 
 C 62.8 (19.2) 43 53   4 DA_a 69.5 (15.3) 27 70   3 
     oc risk*  DA 55.6 (18.9)   3 65 32 DA_b 52.6 (17.7)   2 73 24 
 C 55.5 (21.7)   7 54 39 DA_a 48.7 (20.5)   5 72 23 
Cure bc*   DA 60.4 (21.3) 49 43   8 DA_b 61.9 (24.2) 39 50 11 
 C 56.2 (12.4) 59 32   9 DA_a 68.0 (17.1) 34 58   8 
Cure oc* † DA 44.7 (22.0) 33 38 37 DA_b 37.9 (26.7) 48 24 28 
 C 45.3 (26.9) 39 24 29 DA_a 40.4 (22.4) 32 47 21 
bc risk after PM DA 10.3 (15.0) 37 43 20 DA_b 8.1 (9.3) 41 41 18 
 C 15.8 (20.8) 30 38 32 DA_a 8.7 (9.4) 38 42 20 
oc risk after PO DA   8.7 (14.4) 50 32 18 DA_b 6.3 (9.3) 48 39 13 
 C 13.0 (20.5) 41 32 27 DA_a 6.7 (6.8) 45 38 17 
C, control; bc, breast cancer; oc, ovarian cancer; PM, prophylactic mastectomy; PO, prophylactic oophorectomy. 
* P < 0.05 for risk accuracy comparing the DA and control groups. † P < 0.05 for risk accuracy comparing the 
DA_b and DA_a groups. 
 
DISCUSSION 
 
The present study is the first to evaluate the impact of a DA and its timing in women 
being tested for a BRCA1/2 mutation. Both women with and without a previous 
history of cancer were included. The brochure and video were designed to help women 
make informed decisions, and concentrated on contrasting the various risks and 
benefits of screening and prophylactic surgery and the physical, emotional, and social 
consequences. The DA had no impact on well-being. The DA led to more 
considerations towards prophylactic surgery and corroborating higher valuations for 
prophylactic surgery. The DA had no impact on strength of treatment preference, 
decision uncertainty, and preference for decision making. The DA improved 
information related outcomes. In general, timing of the DA had no impact on any of 
the outcome measures. No interactions were found between the DA and history of 
cancer. 
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Previous studies on genetic testing for a BRCA1/2 mutation did not find substantial 
psychological morbidity among women initiating genetic testing or receiving a positive 
test result [19-25], which is in agreement with the well-being levels in our study. The 
DA had no negative impact on a broad range of well-being outcomes, and did not deter 
women from receiving their test result, while it improved understanding of the 
treatment options and consequences. Similar results on the use of a video in BRCA1/2 
counselling have been reported [26]. Their video, however, was more general and 
introductory and less focussed on the treatment decision. Another difference is that it 
was provided either before or after the first genetic counselling session, whereas our 
information was provided after a blood sample was taken or after a positive test result.  
Women in the DA group were more inclined towards prophylactic surgery. This 
was surprising as the DA was judged to be balanced in a pretest. It also described the 
negative consequences of prophylactic surgery in words and pictures. The trend of the 
decision towards prophylactic surgery, while interesting, is not a valid criterion for 
judging the DA. Therefore, a more relevant question is whether the DA led to a 
reduction of decision uncertainty, and whether it stimulated a preference for a more 
active role in decision making; our results did not show such benefits despite the fact 
that women felt better informed about the treatment options. As our DA was simple 
and was to be viewed at home, that is without face-to face support, a more intensive 
DA might prove more effective [10]. 
The largest and most consistent benefits of DAs are better knowledge and more 
realistic expectations of treatment options [10]. We also found that women felt better 
informed, were more satisfied with the amount and quality of the information, and had 
more accurate risk perceptions, after viewing the DA. A clear marker of the 
information need is that most women viewed the DA, and about half of the women 
viewed the DA twice or more.  Only a few women did not want to see the DA while 
awaiting their test result. Despite improvements in risk perception, on average 60% of 
women in the DA group still had risk perceptions that were inconsistent with a broadly 
defined range of accuracy. Further research is needed to enhance risk perception. The 
positive effects of our DA occurred irrespective whether it was presented before or 
after the test result.  
The strength of our study is that we included a consecutive sample of women 
covering the eastern part of the Netherlands. Some limitations should be considered. 
First, we did not evaluate the impact of timing of the DA in women receiving an 
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inconclusive test result (n = 181). This was beyond the scope of our study, which 
focused on mutation carriers subsequently. Second, the subsample of mutation carriers 
is relatively small reducing the power to detect meaningful differences between the 
women who received the DA either before or after the test result. Third, all treatment 
choices, even those obtained 2 weeks after a positive test result, are merely intentional 
as prophylactic surgery is usually postponed for several months until all specialists 
have been consulted or even longer in young women. However, additional clinical 
follow-up showed that intended treatment choices, obtained shortly after a positive test 
result (T3), are strongly predictive of the executed treatment at 9 months after a 
positive test result: for example, 53% of the women opting for prophylactic 
mastectomy had undergone this treatment, compared to none of the women opting for 
breast cancer screening. Fourth, long-term follow-up on the effects of the DA was not 
obtained because all mutation carriers eventually had received the DA. In the second 
part of our study, evaluating another DA, including trade-offs and a formal treatment 
advice derived from a decision model [9], the follow-up of these mutation carriers will 
be continued. The brochure was based on the best knowledge available at that time and 
needs regular updates. Our results showed that it does not matter whether the DA is 
given to women before or after disclosure of the BRCA1/2 test result. However, in the 
waiting period before the test result, women do benefit from the DA on information 
related outcomes such as subjective knowledge, satisfaction with amount and quality 
of information, and risk perception. Only few women may prefer to postpone the DA 
until being tested positive. Positive effects occurred irrespective of history of cancer; 
thus the DA is considered useful both for women with and without a previous history 
of cancer. Therefore, our advice is to offer the DA, in addition to genetic counselling, 
to all women on a voluntary basis after taking the blood sample, while making clear 
that the information is also available after the test result.  
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APPENDIX  
 
Summary of information presented in the brochure 
 
Introduction 
Aim of information material: supplementary information to genetic counselling. 
General information:   procedures at the Family Cancer Clinic, patterns of inheritance, 
outline of choices. 
 
Breast cancer 
Sporadic breast cancer:  11% life time risk [1], mostly occurs after the age of 50, general risk 
factors. 
Hereditary breast cancer:  35 - 50% risk before age 50, 60 - 85% lifetime risk [2,3], 
characteristics of hereditary breast cancer.  
  
Breast cancer screening 
Efficacy:    80% of breast cancers detected in early stage during screening, 70 - 
75% of these breast cancers are curable [4]. Prognosis about the same 
as sporadic breast cancer [5], not everybody will develop breast 
cancer during screening. 
Procedure:    generally from age 25, monthly breast self-examination, 6-monthly 
physical examination by a physician, yearly mammography.  
Additional information:  surgery for breast cancer, future developments, MRI, biopsies.  
Psychosocial consequences:  more awareness of physical symptoms of the body sometimes may 
lead to more physical complaints, worse psychological well-being in 
some women due to fear of cancer, which may affect marital 
relationships. Better coping with the situation over time. 
 
Prophylactic mastectomy 
Efficacy:    small remaining risk of breast cancer [6]. 
Procedure:   about 1 week admission in hospital, healing of wound takes some 
time, mostly without complications, no lymphoedema.  
Additional information:  breast reconstruction and alternatives, consequences and 
complications 
Psychosocial consequences:  mostly a deliberated choice and therefore better accepted, feelings of 
relieve, negative impact on body image and sexuality in some 
women. Better cooping with situation over time. 
 
Ovarian cancer 
Sporadic ovarian cancer:  1.8% life time risk [1], mostly occurring at age 45 - 60, general risk 
factors. 
Hereditary ovarian cancer:  BRCA1 40 - 60% lifetime risk, BRCA2 15 - 20% life time risk, low 
risk before age 40, sharp increase from age 40 [2,3]. 
 
Ovarian cancer screening 
Efficacy:    efficacy unproven, 25% of ovarian cancer detected in early stage in 
unscreened population [7], 40-45% of hereditary ovarian cancer is 
curable, indication of better prognosis for hereditary as compared to 
sporadic ovarian cancer [8], not everybody will develop ovarian 
cancer during screening. 
Procedure:    generally from age 35, yearly transvaginal ultrasound, gynaecologic 
examination, CA125 testing. 
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Additional information:  future developments, biopsies, surgery for ovarian cancer. 
Psychosocial consequences:  more awareness of physical symptoms of the body sometimes may 
lead to more physical complaints, worse psychological well-being in 
some women due to fear of cancer, which may affect marital 
relationships. Better cooping with the situation over time. 
 
Prophylactic oophorectomy 
Efficacy:    small remaining risk of ovarian cancer [9]. 
Procedure:   mostly around age 40, about 2 days admission in hospital, usually 
laparoscopic surgery with minimal morbidity, after surgery ongoing 
CA125 control. 
Additional information:  menopause and consequences (increased risk for cardiovascular 
diseases and osteoporosis), hormone replacement therapy and 
consequences. 
Psychosocial consequences:  most complaints due to effect of menopause. 
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ABSTRACT 
 
Purpose: To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 
mutation carriers who have to make a choice between screening and prophylactic 
surgery for breasts and/or ovaries.  
Patients and Methods: The SDMI consisted of two value assessment sessions, using 
the time trade-off method, followed by individualized treatment information based on 
(quality-adjusted) life expectancy. After the baseline assessment (2 weeks after a 
positive DNA test result), women were randomly assigned to the SDMI group (n = 44), 
receiving the SDMI 2 months after the test result, or to the control group (n = 44). The 
short- and long-term effects, 3 and 9 months after the test result, were assessed using 
questionnaires. Data were collected on well-being, treatment choice, and decision-
related outcomes.  
Results: In the short term, the SDMI had no effect. In the long term, with respect to 
well-being, patients in the SDMI group had less intrusive thoughts (P = 0.05) and 
better general health (P = 0.01) and tended to be less depressed (P = 0.07). With 
respect to decision-related outcomes for the breasts, the SDMI group held stronger 
preferences (P = 0.02) and agreed more strongly to having weighed the pros and cons 
(P = 0.01). No effect was found on treatment choice. In the long term, interaction 
effects between the SDMI and cancer history were found. The SDMI showed an 
overall beneficial effect for unaffected women, whereas affected women tended to 
experience detrimental effects. 
Conclusion: We conclude that the SDMI improved decision making in unaffected 
BRCA1/2 mutation carriers. Supporting decision making in a systematic way using 
trade-offs is beneficial for these women. 
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INTRODUCTION 
 
The identification of the BRCA1 and BRCA2 genes has created the possibility to test 
for inherited susceptibility of breast and ovarian cancer [1,2]. BRCA1/2 mutation 
carriers, unaffected with cancer, have a high lifetime risk of developing breast (56% to 
85%) and ovarian cancer (16% to 63%) [3-5]. BRCA1/2 mutation carriers already 
affected with breast cancer have a high risk of developing a second breast cancer (up to 
63%) [6]. In the Netherlands, options available to BRCA1/2 mutation carriers are 
intensive screening or prophylactic surgery, including prophylactic mastectomy and 
prophylactic oophorectomy. Screening of breasts and ovaries is associated with the risk 
of cancer that may be detected too late for effective treatment. Although prophylactic 
surgery gives a significant reduction in cancer risk and can also be successful in 
reducing cancer worries [7], it may cause adverse psychological and social outcomes in 
some women [8]. Thus BRCA1/2 mutation carriers are confronted with a difficult 
dilemma in which a trade-off between duration and quality of life plays a crucial role.  
There is a movement toward greater patient involvement in treatment decisions, 
which is often referred to as shared decision making. Shared decision making 
recognizes that there are complex trade-offs in the treatment choice. Shared decision 
making also addresses the ethical need to fully inform patients about the risks and 
benefits of the treatment options, as well as the need to ensure that patients' values play 
a prominent role. For medical decisions with more than one reasonable option, patient 
participation in decision making is necessary to make treatment decisions, taking 
patient values into account. The actual tools to help with shared decision making are 
called decision aids (DAs). 
Decision aids (DAs) can be used as an adjunct to standard counseling to prepare 
patients for decision making. According to the Cochrane definition, DAs are 
interventions designed to help people make a specific and deliberative choice among 
options by providing information on the options and outcomes, relevant to a person’s 
health status [9]. A variety of formats can be used. The most common formats are 
brochures, audio- and videotapes, decision boards, and interactive computer programs 
[9]. Some DAs include tasks to clarify individual values to promote better congruence 
between the individual values and the treatment choice; however, this is an 
understudied area [10]. A systematic review of randomized trails has shown that DAs 
improve patient knowledge, comfort, and participation in decision making [9]. It is not 
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clear which type of DA is most powerful although more comprehensive programs seem 
to have larger effects [9].  
The goal of our study was to evaluate the use of DAs in women testing for a 
BRCA1/2 mutation. DAs may facilitate decision making for these women by helping 
them to arrive at an informed, preference-based treatment choice. We conducted a 
shared decision making study that included two different interventions. In the first part 
of the study, we evaluated the effects of an informative DA and its timing before or 
after testing positive for a BRCA1/2 mutation [11]. This DA consisted of a brochure 
and video providing information on screening and prophylactic surgery. In the second 
part of the study, reported here, we evaluated the effects of a shared decision making 
intervention (SDMI) in BRCA1/2 mutation carriers on well-being, treatment choice, 
and decision related outcomes. The SDMI consisted of two value assessment sessions, 
by use of the time trade-off (TTO) method [12] followed by individualized treatment 
information based on life expectancy (LE) and quality-adjusted life expectancy 
(QALE) derived from decision analysis [13]. Decision analysis offers a method to 
combine individual values regarding treatment outcomes with individual risk profiles. 
For the treatment choice for BRCA1/2 mutation carriers, individual values were shown 
to be important [13-17]. Although such interventions have been described previously 
[18-23], they have mainly concentrated on the impact of patient preferences on 
treatment choice, whereas in our study we focus on a much broader range of outcomes. 
 
PATIENTS AND METHODS 
 
Study population 
The study was implemented in the Family Cancer Clinics of the University Hospitals 
of Nijmegen (beginning March 1999), Groningen (beginning June 1999), and 
Maastricht (beginning January 2000). Study entry closed in November 2001. Both 
women affected and unaffected with breast/ovarian cancer who had chosen to undergo 
DNA testing were eligible. Women were excluded if they were unable to give 
informed consent, had insufficient knowledge of the Dutch language, were diagnosed 
with distant metastases, had undergone both bilateral mastectomy and oophorectomy, 
or had been treated with chemotherapy, radiotherapy, or surgery for breast/ovarian 
cancer less than 1 month before blood sampling. Women were ongoing in the study 
only when a deleterious BRCA1/2 mutation was found. 
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SDMI 
The SDMI was provided by a trained research assistant and consisted of three sessions 
with an interval of 1 to 2 weeks. In the first session, individual values for the treatment 
options (screening and prophylactic surgery) were assessed in a face-to-face interview 
by use of the TTO method [12]. In the second session, the TTO interview was repeated 
by telephone. The questions asked in the face-to-face and telephone interview were 
identical. In a previous study, in a comparable study sample, we judged the TTO 
method to be feasible, reliable, and valid [24] and strongly predictive of treatment 
intentions [25]. Many women commented that the trade-off task led to a thoughtful 
evaluation of the health outcomes and considered the trade-off to be relevant [24]. The 
TTO interview is described in detail in the next paragraph. Decision analysis was used 
to arrive at individualized treatment information based on LE and QALE [13]. QALE 
is calculated by multiplying the TTO value by the LE: TTO values were used as a 
weighing factor to adjust the remaining life years for the quality of life that will be 
experienced. In the third session, individualized treatment information was shared with 
the women using two bar charts, one for LE and one for QALE. The bar charts 
presented the treatment options relative to each other (see Appendix). Absolute LE and 
QALE information was not given because we also included women with cancer, who 
were not always fully aware of their prognosis. However, we did present the absolute 
gains and losses in LE and QALE of prophylactic surgery compared with screening. To 
avoid the derivation of prognosis, the bar charts were not to be taken home. 
 
TTO interview 
The TTO interview started with an introduction, an example, and a flow-chart in which 
the women had to answer a series of questions [26]. The value assessment started as 
follows: the health states following the treatment options were described in bullet-point 
format on laminated cards, and the women were asked to rank them in order of 
preference. Values for each health state were then elicited with a flow-chart using the 
TTO method [26]. Women were asked to choose between two certain options. Option 
1 is to continue living with prophylactic surgery for a fixed time t (such as the rest of 
life until age 80 years). Option 2 is to continue living with screening for a time x less 
than t. Using forced choices, we found how many years (x) in the health state screening 
was equivalent to a defined time (t) in the poorer health state prophylactic surgery. 
Time was used as the unit of comparison. By comparing the two times x and t, the 
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value for each health state could be calculated. The TTO value for prophylactic surgery 
was calculated as x/t. For example, a respondent who was indifferent between living 
with prophylactic surgery for 40 more years and living with screening for 20 more 
years was assigned a TTO value of 0.5 (20/40) for prophylactic surgery. We used the 
ping-pong technique to identify the indifference point. This involved alternating 
between long- and short-term time periods x for screening. To mitigate any ordering 
effects, the presentation of health states was randomly allocated before the interview. 
 
Study procedure 
Data described here were collected during a longitudinal randomized study (T1 to T5) 
evaluating an informative DA and its timing (T1 to T3) [11] and the SDMI (T3 to T5; 
Figure 1). The study was approved by the hospital ethics boards. Clinical geneticists or 
genetic counselors briefly introduced the study after a blood sample for BRCA1/2 
testing was obtained. A research assistant subsequently contacted these women by 
phone to confirm eligibility and to discuss the study. Women who gave verbal consent 
were enrolled and were mailed an informative letter describing the study and a consent 
form. 
 In the first part of the study (T1 to T3; Figure 1) [11], not reported here, women 
were randomly assigned to the DA group (the DA was provided 2 weeks after blood 
sampling) or to the control group (receiving usual care). The DA was added to usual 
care and was to be viewed at home. It consisted of a brochure and video providing 
information on screening and prophylactic surgery, and the physical, emotional, and 
social consequences. At T2 (4 weeks after blood sampling), the DA group was 
compared with the control group. After testing positive, the control group too received 
the DA. At T3, 2 weeks after disclosure of a positive test result, we compared the 
impact of timing (before of after a positive test result) of the DA. The DA had positive 
effects on information related outcomes only (subjective knowledge, satisfaction with 
information, and risk perception); timing of the DA had no effect [11]. Women were 
ongoing in the study only if a deleterious BRCA1/2 mutation was found. 
In the second part of the study (T3 to T5; Figure 1), described here, T3 formed 
the baseline assessment for the evaluation of the SDMI. After T3, women were 
randomly assigned to the SDMI group or to the control group (receiving usual care). 
The SDMI was added to usual care and was scheduled 2 months after the test result. 
This time point was chosen so that information from the consultations with the 
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specialists from the Family Cancer Clinic could be weighed into the trade-offs. These 
consultations usually take place within 1 to 2 months after disclosure of a positive test 
result. At T4 and T5, 3 and 9 months after the test result, a follow-up questionnaire 
was sent to evaluate the short- and long-term effects of the SDMI. 
 
 
 
 
Figure 1. Study design: T1 to T3, first part of the study (not reported here); T3 to T5, second part of the study 
(reported here). X, usual care; DA, (informative) decision aid; SDMI, shared decision making intervention. 
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Outcome measures 
All measures were obtained at baseline (T3) and at short- (T4) and long-term follow-
up (T5), unless indicated otherwise. 
 
Well-being 
We collected data on anxiety (state anxiety subscale of the Spielberger State-Trait 
Anxiety Inventory) [27], depression (Center for Epidemiologic Studies Depression 
Scale) [28], and intrusive and avoidance thoughts about cancer in the family (intrusion 
and avoidance subscale from the Impact of Event Scale) [29]. Furthermore, women 
were asked to rate their general health during the last week on an 11-point scale (0, 
very bad; 10, excellent). 
 
Treatment choice 
Women were asked to indicate their intended treatment choice for the breasts and/or 
ovaries. When women had no breasts or ovaries because of previous curative or 
prophylactic surgery, this question was not applicable. Intended treatment choice 
included “prophylactic surgery”, “screening”, and “undecided”. To test differences in 
intended treatment choice, it was dichotomized in prophylactic surgery versus the rest 
(screening and undecided). We have combined the treatment choice screening with 
undecided, because these women will receive the same clinical treatment, namely, 
screening. Also, the undecided group was too small: undecided choices decreased from 
2% to 1% for the breasts, and from 5% to 0% for the ovaries for T3 and T5, 
respectively. Furthermore, women were asked to rate prophylactic surgery and 
screening on a 10-point rating scale (1, very bad; 10, excellent) in answering the 
question “How suitable do you find prophylactic mastectomy for yourself?”. Data on 
the actually performed treatment were also collected by questionnaire.  
 
Decision related outcomes 
The decision related outcomes were asked separately for the breasts and ovaries. When 
women had no breasts or ovaries because of previous curative or prophylactic surgery, 
these questions were not applicable.  
Strength of treatment preference. Strength of treatment preference was asked 
for the treatment options prophylactic surgery and screening on a four-point Likert 
scale (1, weak preference; 4, very strong preference). Those who had chosen 
“undecided” as treatment choice were assigned a value of zero (no preference). 
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Decision uncertainty. Decision uncertainty was measured with three items related to 
the uncertainty subscale of the Decisional Conflict Scale by O’Connor [30]. Our items 
were “I doubt what to choose”, “This decision is hard for me to make”, and “I am not 
sure what to choose”, measured on a five-point scale (1, strongly disagree; 5, strongly 
agree). A sum score was created by averaging the items.  
Perceived participation in decision making. Perceived participation in decision 
making was measured with two decision making items from the Problem-Solving 
Decision-Making Scale (PSDM) from Deber et al [31]. The items were as follows: 
“Given the risks and benefits of the possible treatment options, who has decided how 
acceptable those risks and benefits are for you?” and “Who has decided which 
treatment option should be selected?” measured on a five-point scale (1, doctor alone; 
3, doctor and I equally; 5, I alone). A sum score was created by averaging the items. 
This item had no baseline assessment. 
Weighing treatment choice. Because trade-offs were prominent in the SDMI, we 
included a single item, “I weighed the pros and cons”, from a Decision Evaluation 
Scale (Stalmeier et al, manuscript submitted for publication). It was measured on a 
five-point scale (1, strongly disagree; 5, strongly agree). This item had no baseline 
assessment. 
Perceived preference of the specialists. Women were asked whether they felt 
that the specialists held a treatment preference (yes/no) and, if so, its strength 
(strong/weak). We combined the two answers in “strong preference” versus “weak or 
no preference”. These items were only asked at T4. 
 Support and advice from specialists. Women were asked whether they had 
wanted more support and advice from their specialists regarding their treatment choice 
on a seven-point scale (1, strongly disagree; 7, strongly agree). These items were only 
asked at T4. 
 
Sample size and power 
We assumed that the SDMI would have a larger effect on decision uncertainty than our 
informative DA [11]. The SDMI is face-to-face and more intensive, and the sample 
consisted of BRCA1/2 mutation carriers who are actually facing the choice between 
screening and prophylactic surgery. To detect a difference of at least 25% in the 
decision uncertainty score between the two groups with a 5% two-sided significance 
level and a power of 80%, we needed a sample size of 45 women in each group.  
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Randomization and blinding 
Randomization of the SDMI took place by family (first-degree up to and including 
third-degree relatives) to avoid contamination. The randomization schedule, stratified 
by medical history of breast/ovarian cancer and by timing of the informative DA, was 
generated by computer in blocks of 10. Neither study participants nor members of the 
study staff were blinded to intervention assignment.  
 
Statistics 
Data were analyzed using the Statistical Package for the Social Sciences (SPSS 10.0.5; 
SPSS Inc, Chicago, IL). We analyzed data on an intention-to-treat basis. For missing 
items from multi-item scales, we imputed the mean of the remaining items when at 
least half of the items were completed. To identify potential confounding variables, we 
compared the SDMI and control group on baseline characteristics using 2 tests for 
categoric variables and Student’s t-tests for continuous variables.  
To evaluate the effects of the SDMI, we compared the SDMI and control group 
on the outcome measures. For continuous measures, comparisons were done using 
analyses of covariance [32], including, when present, the baseline assessment as a 
covariate. Effect sizes were calculated as the adjusted mean of the SDMI group minus 
the adjusted mean of the control group divided by the SD of the difference score. 
When no baseline assessment was present, effect sizes were calculated from the 
unadjusted mean scores. For the two categorical variables of treatment choice and 
perceived preference of the specialists, comparisons were made using 2 tests. We used 
a P level of 0.05 to indicate statistical significance. The number of subjects providing 
data for the various analyses varied because of missing data and because of 
nonapplicability of some questions. 
Because randomization took place by family, and because family members were 
not independent on the outcome measures, statistical significance will be inflated when 
all women are treated as independent units. The sample contained nine families with 
multiple members (range, two to three members), with a total of 21 women. To counter 
inflation, we further examined significant effects by incorporating only the first 
included family member in the analyses.     
Because previous findings showed that women affected with breast or ovarian 
cancer experienced a worse well-being than unaffected women [33], we included 
cancer history in the primary analyses to examine the interaction effect between the 
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SDMI and cancer history. Furthermore, we conducted separate analyses for women 
affected and unaffected with cancer to report the various effect sizes. 
 
Table 1. Baseline characteristics 
 SDMI (%) 
(n = 44) 
Control (%) 
(n = 44) 
Sociodemographics   
     Age, years    
          Mean 39.1 39.9 
          SD  9.7 10.4 
              Range: 20-39  48 57 
              40-49  36 20 
              50-65  16 23 
     Currently married/partner 84 86 
     College or higher 39 34 
     Employed 68 73 
     Have children 66 77 
     Want (more) children 23 26 
     Religiously affiliated  55 70 
Medical history   
     Personal medical history of bc/oc   
     No cancer 75 71 
     Breast cancer only 25 29 
     Ovarian cancer only   0   0 
     Breast and ovarian cancer   0   0 
Family medical history of bc/oc   
     Breast cancer only 31 23 
     Ovarian cancer only   3   2 
     Breast and ovarian cancer 66 75 
     Proband 25 25 
     First degree relatives with bc or oc 68 75 
     First degree relatives died of bc or oc 34 30 
Allocation of informative DA   
     Before test result 49 51 
     After test result 51 49 
Abbreviations: SDMI, shared decision making intervention; SD, standard deviation; bc, breast cancer; oc,  
ovarian cancer; DA, decision aid. 
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RESULTS 
 
Participants 
Figure 1 presents the study design for the whole study (T1 to T5). At study entrance, 
453 women were eligible and 390 (86%) gave informed consent [11]. After the first 
part of the study (T1 to T3), 89 women were eligible for the second part of the study 
reported here (T3 to T5). One woman withdrew after T3 because of high emotional 
distress. Of the remaining 88 women, 44 women were randomly assigned to the SDMI 
group and 44 women to the control group. In the SDMI group, two women did not 
receive the SDMI, one unaffected woman because her mother just had died of breast 
cancer and one affected woman because she had already undergone both bilateral 
mastectomy and oophorectomy. The follow-up at T4 was 100%. At T5, one woman 
from the control group was lost to follow-up. 
 
Baseline characteristics 
No significant differences were found between the SDMI and control group (Table 1). 
The stratification for medical history and for the allocation of timing of the informative 
DA was successful. 
 
Well-being 
In the short term (Table 2, T4), the SDMI had no effect on any of the well-being 
outcomes. In the long term (Table 2, T5), the SDMI group had less intrusive thoughts 
about cancer in the family (F1,83= 3.91; P = 0.05; effect size [d] = - 0.30), a better 
general health (F1,79 = 6.53; P = 0.01; d = 0.40), and tended to be less depressed (F1,84 = 
3.40; P = 0.07; d = - 0.28). No effect was found on anxiety. 
 
Treatment choice 
Intended treatment choice was only asked when applicable. At baseline (T3), short 
(T4), and long term (T5), no differences were found between the SDMI and control 
group, neither on the intended treatment choice nor on the actually performed 
treatment for breasts and ovaries (data not shown). No differences were found for the 
ratings of the treatment options (data not shown).  
Overall, 33% (28 of 85 patients) intended to undergo prophylactic mastectomy 
at T3, of whom 50% (n = 14) had undergone this treatment at T5; none of the other 
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women had undergone prophylactic mastectomy at T5. Overall, 68% (56 of 82 
patients) intended to undergo prophylactic oophorectomy at T3, of whom 54% (n = 30) 
had undergone this treatment at T5; four of the other women had undergone 
prophylactic oophorectomy at T5.  
 
Decision related outcomes  
With respect to the decision related outcomes for the breasts, in the short term (Table 
3, T4), no effects were found. In the long term (Table 3, T5), the SDMI group held 
stronger treatment preferences (F1,68 = 6.11; P = 0.02; d = 0.41) and more strongly 
agreed to having weighed the pros and cons (F1,69 = 6.45; P = 0.01; d = 0.42); no 
effects were found for the other decision related outcomes. With respect to the decision 
related outcomes for the ovaries, no effects were found, neither in the short nor in the 
long term (data not shown). 
With respect to the behavior of the specialists, more women in the SDMI group 
(29%) felt that the specialists held a strong preference for one or the other breast 
treatment compared with the control group (3%; 2 = 10.47; P = 0.001). This 
difference was not found for the ovaries; 33% in the SDMI group, and 35% in the 
control group experienced a strong preference (2 = 0.03; P = 0.87). Although not 
significant, women in the SDMI group wanted more support and advice from the 
specialists regarding their treatment choice for the breasts (F1,78 = 2.94; P = 0.09; d = 
0.27); this finding was less strong for the ovaries (F1,74 = 2.22; P = 0.14; d = 0.24). 
 
Additional analyses: controlling for family  
Significant differences found above were further tested by including only the first 
family member. Therefore, 12 persons were excluded from the analyses, seven from 
the SDMI group and five from the control group. Only the long term effect on 
intrusion became insignificant (F1,71 = 2.14; P = 0.15; d = 0.24).  
 
 
 Table 2. Unadjusted scores for well-being, results of the ANCOVA, and effect sizes 
 Group n T3 
Mean (SD) 
T4 
Mean (SD) 
F P d n T3 
Mean (SD) 
T5 
Mean (SD) 
F P d 
Anxiety (STAI-state) SDMI 43   39.5 (12.2)  35.4 (11.7) 0.26 0.61 -0.08 44  39.1 (12.4) 33.2 (12.1) 1.58 0.21 -0.19 
 Control 43   41.3 (12.7)  37.4 (10.7)    43  42.0 (12.7) 37.5 (11.7)    
Depression (CESD) SDMI 43   9.8 (9.9)  5.5 (7.5) 1.93 0.17 -0.21 44  9.6 (9.9)  5.8 (7.4) 3.40 0.07 -0.28 
 Control 43   10.5 (10.4)  7.5 (7.3)    43  10.9 (10.3)    9.3 (10.1)    
Intrusion (IES) SDMI 42 13.2 (9.7)  9.4 (7.4) 1.23 0.27 -0.17 43 12.8 (9.8)  8.1 (8.3) 3.91  0.05* -0.30 
 Control 43 12.7 (9.0) 10.4 (7.7)    43 12.8 (8.8) 10.9 (8.5)    
Avoidance (IES) SDMI 42   8.9 (6.8)  5.8 (6.2) 0.39 0.53 -0.10 43  8.7 (6.9)  5.7 (5.9) 1.42 0.24 -0.18 
 Control 43   8.0 (6.4)  6.0 (5.7)    43  8.3 (6.3)  6.8 (6.4)    
General health SDMI 40   7.4 (1.9)  7.6 (1.9) 0.72 0.40 -0.14 42  7.5 (1.9)  8.1 (1.4) 6.53  0.01*  0.40 
 Control 38   7.5 (1.7)  7.9 (1.3)    40  7.4 (1.7)  7.3 (1.6)    
Abbreviations: ANCOVA, analysis of covariance; SD, standard deviation; d, effect size; STAI, State-Trait Inventory; SDMI, shared decision making intervention; CESD, 
Center for Epidemiologic Studies Depression Scale; IES, Impact of Event Scale. 
* P < 0.05  
     
 
Table 3. Unadjusted scores of decision related outcomes for the breasts, results of the ANCOVA, and effect sizes 
 Group n T3 
Mean (SD) 
T4 
Mean (SD) 
F P d n T3 
Mean (SD) 
T5 
Mean (SD) 
F P d 
Strength of preference  SDMI 38 2.9 (0.9) 3.3 (0.7) 0.46 0.50   0.11 35 2.9 (0.9) 3.3 (0.8) 6.11  0.02*   0.41 
 Control 42 2.9 (0.9) 3.2 (0.9)    36 2.9 (1.0) 2.9 (0.9)    
Decision uncertainty SDMI 38 2.3 (1.0) 2.1 (0.9) 0.58 0.45 -0.12 35 2.3 (1.0) 2.2 (0.9) 1.97 0.17 -0.23 
 Control 42 2.4 (1.2) 2.3 (1.0)    36 2.5 (1.2) 2.6 (1.0)    
Weighing treatment choice SDMI 38 X 4.2 (0.6) 2.00 0.16   0.22 35 X 4.3 (0.5) 6.45  0.01*   0.42 
 Control 41 X 4.0 (0.6)    36 X 3.9 (0.5)     
Perceived participation in DM SDMI 37 X 4.1 (0.6) 2.72 0.10   0.26 35 X 4.0 (0.7) 0.66 0.42   0.14 
 Control 41 X 3.9 (0.7)    36 X 3.9 (0.6)    
Abbreviations: ANCOVA, analysis of covariance; d, effect size; SD, standard deviation; SDMI, shared decision making intervention; X, no baseline assessment; DM, decision 
making. 
* P < 0.05 
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Interaction effects between SDMI and cancer history  
In the short term, no interaction effects between the SDMI and cancer history were 
found for any of the well-being or decision related outcomes. In the long term, with 
respect to well-being, an interaction effect was found for anxiety (F1,82 = 4.36; P = 
0.04) and general health (F1,77 = 5.71; P = 0.02). With respect to the decision related 
outcomes for the breasts, an interaction effect was found for strength of preference  
(F1,66 = 3.81; P = 0.05), decision uncertainty (F1,66 = 9.80; P < 0.01) and participation 
preference (F1,67 = 4.64; P = 0.04). With respect to the decision related outcomes for 
the ovaries, an interaction effect was found for strength of preference (F1,42 = 12.93; P 
< 0.01) and decision uncertainty (F1,42 = 17.04; P < 0.01). 
The size of the differential impact in affected versus unaffected women is 
presented in Table 4.   From the separate analyses for affected and unaffected women, 
only effect sizes are reported for well-being and decision related outcomes for the 
breasts. In the short term (Table 4, T4), the SDMI had no effect on affected nor on 
unaffected women. In the long term (Table 4, T5), for unaffected women, beneficial 
effects were found on all outcome measures and most were significant. The effect sizes 
were larger for unaffected women compared with the whole group (Table 2, Table 3, 
T5). For affected women, insignificant detrimental effects were found on the above-
mentioned outcomes for which an interaction effect was found.  
 
Table 4. Effect sizes of the SDMI for affected versus unaffected women 
 T4 T5 
 Affected Unaffected Affected Unaffected 
Well being1     
     Anxiety - 0.15 - 0.05    0.27  - 0.41* 
     Depression - 0.19 - 0.17    0.05  - 0.40* 
     Intrusion   0.12 - 0.26    0.09   - 0.48** 
     Avoidance   0.19 - 0.10    0.10 - 0.22 
     General Health - 0.26   0.00 - 0.28      0.58** 
Decision related outcomes; breasts2     
     Strength of preference - 0.02   0.15 - 0.25      0.57** 
     Decision uncertainty   0.19 - 0.23    0.61   - 0.56** 
     Weighing treatment choice   0.13   0.27 - 0.12     0.59** 
     Perceived participation in DM   0.37   0.19 - 0.52   0.32 
1 Number of patients per group varied from 10 to 12 for affected and from 29 to 33 for unaffected women. 
2 Number of patients per group varied from five to 11 for affected and from 27 to 31 for unaffected women.  
*   P < 0.05 
** P < 0.01 
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DISCUSSION 
 
We evaluated a SDMI for BRCA1/2 mutation carriers who were facing the choice 
between screening and prophylactic surgery for the breasts and/or ovaries. The SDMI 
consisted of trade-offs and individualized treatment information. To our knowledge, 
this is the first randomized study to evaluate such an intervention on a broad range of 
outcomes as a decision support tool. Previous studies, combining value assessment and 
decision analysis, have mainly concentrated on the impact of patient preferences on 
treatment choice [18-23]. In the short term, 3 months after the test result, the SDMI 
had no effect. In the long term, 9 months after the test result, the SDMI group reported 
less intrusive thoughts about cancer in the family, better general health, and a trend 
towards less depressive thoughts. Moreover, they reported a stronger treatment 
preference and more strongly agreed to having weighed the pros and cons for the 
breast treatment. It is noteworthy that two previous studies on DAs also found stronger 
effects in the long term [34,35].  
Several types of DAs exist. The issue of what type of DA is most effective is 
still unresolved [9]. Our randomized study shed some light on this issue. The 
informative DA had shown beneficial effects on information related outcomes only 
[11], whereas the SDMI showed beneficial effects on a broader range of outcomes. In 
a previous uncontrolled before-after study of our group, we evaluated the informative 
DA and the SDMI as one package [36]. Then we found beneficial effects on 
information related outcomes as well as on more general outcomes, suggesting that the 
beneficial effects of the two interventions add up. Our current study design, with all 
participants receiving the initial informative DA before the randomization of the 
SDMI, precluded an evaluation of the interaction effects between the informative DA 
and the SDMI. This might be a subject for future research.  
Nevertheless, from the present study, it is unclear which specific element of the 
SDMI is effective. One possible explanation is the additional attention paid by the 
research assistant. However, the time spent with the research assistant was relatively 
short when compared with the time spent with the specialists from the Family Cancer 
Clinic. Perhaps the provision of individualized treatment information is effective. 
However, as our informative DA had only beneficial effects on information related 
outcomes and none whatsoever on well-being and decision related outcomes [11], this 
seems unlikely. Another explanation, which needs to be followed up in future work, is 
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that during decision support, negative emotions are expressed more strongly [37]. This 
is known to enhance well-being over the long term [38].  
On the basis of our own data, we hypothesize that the trade-offs are the 
effective component of the SDMI. These trade-offs explicitly required women to 
consider their values in the light of quality and length of life. The effect of the trade-
offs is evident as women in the SDMI group more strongly agreed to having weighed 
the pros and cons, suggesting a more deliberated treatment choice. This might lead to 
stronger treatment preferences in women from the SDMI group, as indeed we found. 
Furthermore, as these women explored their own preferences, they might more easily 
discern their own preferences from the preferences of the specialists, as indeed we 
found. Our hypothesis is further supported by psychologic work showing that 
contrasting the future with reflections on present reality (the trade-offs have that effect) 
strengthens goal commitments, which may lead to improved well being [39]. If indeed 
the beneficial effects could be attributed to the trade-offs, decision making might be 
improved by actively exploring individual values for the treatment options in a 
systematic way using trade-offs.  
Next to establishing the essential elements of a DA, there is also a need to 
identify the people who are most likely to benefit [9]. In the long term, we found 
various interaction effects between the SDMI and cancer history. Subgroup analyses 
revealed that the SDMI had an overall beneficial effect for unaffected women and 
detrimental effects for affected women, although the SDMI was evaluated equally by 
affected and unaffected women (data not shown). Several explanations may apply. 
First, affected women may have received individualized treatment information that was 
discordant with their treatment intention more often. However, the opposite was found: 
treatment intentions and the best option based on QALE agreed in 70% of the affected 
women and in 44% of the unaffected women. Second, affected women (45 years) were 
older then unaffected women (37 years), and it may be that the SDMI is less effective 
in older women. However, in the unaffected sample, the beneficial effects of the SDMI 
were independent of age. Furthermore, affected and unaffected women did not differ at 
baseline (T3) on other potential explanatory variables such as risk perception and 
preference for decision making (data not shown). So it remains unclear why the SDMI 
is not effective in affected women. Previously, we found that affected women tended 
to react more strongly toward a positive DNA test result [33]. Perhaps the additional 
confrontation with trade-offs is simply too taxing for affected women, in view of the 
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burden of being at risk for a second cancer. Further studies are needed with larger 
sample sizes to confirm these effects.  
In general, DAs are meant to supplement, not replace, the traditional process of 
patient counseling by clinicians. Can the present SDMI be implemented into a Family 
Cancer Clinic? The present study shows it is feasible to implement such an 
intervention in the clinic within a research context. Our study reveals that the SDMI is 
acceptable to women; further study is needed about the acceptability to counselors. 
However, the TTO interview is labor-intensive, requiring on average 1 hour per patient 
when performed face-to-face and 30 minutes when repeated by telephone. The time 
needed to perform the decision analysis, including sensitivity analyses, depends on the 
cancer history. For affected women, the prognosis needs to be determined and included 
in the decision analysis, which may take some hours. For unaffected women, the 
decision analysis takes half an hour. Furthermore, performing TTO interviews, 
conducting individual decision analyses, and sharing treatment information requires 
well-trained personnel. Of course, the SDMI is not complete without using the 
informative DA [11]. This information material and the decision model need to be kept 
up-to-date. Time pressure and costs of implementing decision aids are frequently cited 
as barriers for using decision aids [40]. Despite these barriers, we believe that a 
simplified version of the SDMI, perhaps involving only the trade-offs, can be 
integrated into a consultation with a social worker or genetic counselor. This may not 
require much extra time per patient, as the trade-offs could be used as a basis for 
further deliberations.  
It is acknowledged that some of the significant differences observed in this 
study could be due to chance, given the number of statistical tests. However, for 
unaffected women, all measures consistently pointed in a beneficial direction. 
Furthermore, the sample size is relatively small. Other limitations are that we know 
nothing about its cost effectiveness and how the counselors view the SDMI.  
 We conclude that the SDMI improved decision making in unaffected BRCA1/2 
mutation carriers. Our advice is to support decision making in these women in a 
systematic way using trade-offs. The SDMI is not recommended for affected women. 
Future research should concentrate on how and for whom this intervention could be 
implemented profitably in the clinical practice of Family Cancer Clinics.  
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APPENDIX 
 
Example of individualized treatment information derived from the decision model (BRCA1 mutation 
carrier, age 41 years, performing prophylactic mastectomy (PM) and prophylactic oophorectomy (PO) 
at age 41, risk level: 72.5% cumulative risk of breast cancer and 51.5% cumulative risk of ovarian 
cancer, time trade-off [TTO] value PMPO and PMOS = 0.70, TTO value BSPO = 1).  Gains in 
(quality adjusted) life years are presented relative to BSOS. BS, breast cancer screening; OS ovarian 
cancer screening; LE, life expectancy; QALE, quality adjusted life expectancy. 
 
Life Expectancy
              PMPO        PMOS        BSPO       BSOS
LE
+6.7
+1.3
+5.7
Quality Adjusted Life Expectancy
           PMPO       PMOS       BSPO       BSOS
QALE
-2.6
-4.9 
+5,6
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ABSTRACT 
 
There are several instruments to assess how patients evaluate their medical treatment 
choice. These are used to evaluate decision aids. Our objective is to investigate which 
psychological factors play a role when patients evaluate their medical treatment 
choices. A pool of 36 items was constructed, covering concepts such as uncertainty 
about and satisfaction with the decision, informed choice, effective decision making, 
responsibility for the decision, perceived riskiness of the choice, and social support 
regarding the decision. This pool was presented to patients at high risk for breast and 
ovarian cancer, awaiting a genetic test result, and facing the choice between 
prophylactic surgery or screening. Additional measures were assessed for validation 
purposes. Factor and Rasch analyses were used for factor and item selection. Construct 
validity of emerging scales was assessed by relating them with the additional measures. 
Three factors summarised the psychological factors concerning decision evaluation: 
Satisfaction-Uncertainty, Informed Choice, and Decision Control. Reliabilities 
(Cronbach’s α) of the three scales were 0.79, 0.85, and 0.75, respectively. Construct 
validity hypotheses were confirmed. The first two scales were similar to previously 
developed scales. Of these three scales, the Decision Control scale correlated most 
strongly with the well-being measures, was associated with partner's agreement and 
physician's preferences as perceived by patients, and with a negative emotional 
reaction to the information material. In conclusion, the Decision Control scale is a new 
scale to evaluate decision aids, and it appears to be rooted in health psychological 
theories. 
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INTRODUCTION 
 
An increasing number of studies evaluate the effects of involving patients in the 
medical decision making process [1]. Patients may be involved, for instance through 
the provision of information, through values clarification, or by helping patients to 
formulate their questions. A wide array of outcomes has been used in such evaluations 
including treatment choice and strength of treatment preference, quality of life 
outcomes, psychological outcomes such as anxiety, depression, and decisional conflict, 
satisfaction with care, cognitive outcomes relating to information needs, knowledge 
and risk perception, and outcomes such as use of care, and work absenteeism [2,3]. 
This study focuses on how patients evaluate the treatment decision itself. In 
general, these decision related outcomes are meant to assess how patients evaluate the 
effects of interventions designed to increase patient involvement in decision making, 
and not to distinguish between patients.  
In the study of treatment decisions in the context of decision support 
interventions, two approaches have been followed: (1) assess the patient’s evaluation 
of the decision making process [4]; and (2) assess the patient's evaluation of the 
decision. The first approach deals primarily with the quality of the information 
processing. Improving information processing is an important goal of decision support. 
For example, Hollen [5] developed a taxonomy of decision styles and decision quality 
inventories building on the framework developed by Janis and Mann [6]. Related 
approaches can be found in the coping literature, for instance coping with information 
[7], and Decision Styles Questionnaire [8]. It has been shown that these concepts can 
mediate the effectiveness of patient information material. 
Our interest, however, is the second approach, i.e. the evaluation of the decision 
by patients. Such decision related evaluations have been found to be associated with 
treatment choices [9] or treatment choice intentions [10].   
Several scales have been developed: the Decisional Conflict Scale [9], 
comprising the subscales Uncertainty, and Factors Contributing to Uncertainty, the 
Effective Decision Making scales [9], the Satisfaction with Decision scale [11], the 
Decision Attitude Scale [4], the Satisfaction with decision making process 
questionnaire [12], the Satisfaction with Decision Made Questionnaire [12], the 
Decision Self Efficacy Scale [13], the Decision Emotional Control scale [13], and the 
Decision Regret scale [14]. In general, these scales have shown good internal 
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reliability (Cronbach’s α) and test-retest reliability. Evidence supporting construct 
validity has also been reported. 
  While a wide array of scales exist, it is unclear to what extent these scales assess 
different components of decision evaluation. For instance, Decision Uncertainty and 
Satisfaction with the Decision have generally been found to be strongly correlated 
[9,11]; but whether both scales tap into the same construct is not known. Furthermore, 
some scales (e.g. the Decisional Conflict Scale) do not yield similar factor structures 
when translated into other languages [15].   
Our goal is to uncover the factors underlying the evaluation by patients of 
treatment decisions. It was not our intention to translate existing scales completely or 
literally. Additional concepts were considered. These concepts emerged after 
reviewing the above literature [1-15], and the decision making, social psychological, 
health psychological, and coping literatures. The following concepts were identified: 
(1) affective evaluation including uncertainty and satisfaction with the decision; (2) 
informed choice; (3) effective decision making; (4) responsibility, blame, control; (5) 
perceived riskiness; (6) social support and social approval. The last three concepts are 
not covered by existing scales. Responsibility was added because it may affect 
treatment compliance. Responsibility may modify feelings of regret, which in turn 
affects decision making [16]. Avoiding blame for future accidents is also believed to 
affect decision making [17]. Sense of control is believed to affect health outcomes 
[18]. Perceived riskiness was included because risk is a major dimension in decision 
making [19]. Social support was included because of its importance in models for 
health behaviour and stress.  
 
METHODS 
 
Item construction 
The decision items were developed in Dutch by one of us (PFMS). Some of the items 
were from existing scales, new items were developed for the additional concepts. We 
considered items from the studies discussed above and a questionnaire kindly provided 
by Broadstock and Michie [20]. Items were shortened or adapted to get brief 
unambiguous items. All items were presented to three investigators, of whom two 
investigated medical decision making from the patients perspective, the third was an 
expert in questionnaire construction. Items were discarded when they were deemed 
     
109 
insufficiently clear or indicative of the concept they were meant to operationalise. 
Refinement of this process took place in two extra rounds. As a result, 36 items came 
up. A five-point response scale ranging from “strongly disagree” (1) to “do not 
agree/do not disagree” (3) to “strongly agree” (5) was used. A complete list of concepts 
and items is available, also in Dutch, from the first author. 
 
Study population 
The study was implemented in the Family Cancer Clinics of the University Hospitals 
of Nijmegen, Groningen, and Maastricht in the Netherlands. Both women with and 
without breast/ovarian cancer who had chosen to undergo DNA-testing were eligible.  
 
Procedure 
Original study aims and detailed methods have been published elsewhere [21,22]. 
Questionnaires were sent at baseline, T1, that is after blood sampling to test for a 
BRCA1/2 mutation, at T2, 4 weeks after blood sampling, at T3, 2 weeks after a 
positive test result and at T4, 3 months after a positive test result. Half of the women 
received a video and brochure [21], dealing with the decision between prophylactic 
surgery or screening for breast/ovarian cancer, 2 weeks after the blood sample, 
together with a follow-up questionnaire to evaluate this information. The outcome 
measures have been described in full detail [21,22]. A brief summary is given below. 
 
Measures 
Well-being. Data were collected on anxiety (STAI) [23], depression (CES-D) [24], 
intrusive and avoidance thoughts about cancer in the family (Impact of Event Scale) 
[25], and general health during the last week.  
Treatment choice. At T2, women were asked what treatment was chosen related 
to breast cancer risk. The choice was between “prophylactic mastectomy”, “breast 
cancer screening”, and “undecided”. Women were instructed to imagine that they 
carried the mutation, while answering the items. 
Strength of treatment preference. Strength of treatment preference was asked 
for the treatment options prophylactic mastectomy and screening on a four-point scale 
(1, weak preference; 4, very strong preference). When treatment choice was 
“undecided”, a value of zero (no preference) was assigned.  
Decision items. The items were asked before the genetic test result. In the 
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instruction preceding the items, it was made clear that the items pertained to the choice 
between prophylactic mastectomy and intensive screening for breast cancer. Women 
were instructed to imagine they carried the mutation, while they answered the items. 
Prophylactic mastectomy or breast screening was printed in capitals directly above the 
items on each of the two pages holding the 36 items. Decision items were also asked 
on T4. 
Perceived strength of preference of the specialists. At T4, women were asked 
whether they felt that the specialists held a treatment preference (yes/no) regarding 
treatment for breast cancer, and, if so, its strength (1, weak preference; 2, strong 
preference). If no preference was felt to be present, a value of zero was assigned. 
Partner agreement. Whether or not the partner agreed with their choice was 
asked at T1, using a seven-point response scale ranging from strongly disagree to 
strongly agree. 
Subjective knowledge. Women were asked to rate their knowledge about 
prophylactic mastectomy, breast cancer screening, breast self-examination, 
prophylactic oophorectomy, and ovarian cancer screening. 
Amount of information. The amount of received information for the decision 
related to breast cancer risk was also measured. 
Satisfaction with quality of information. Women were offered a series of 13 
items on the quality of information regarding cancer risks, efficacy of treatment 
options, and physical, emotional, and social consequences.  
Negative emotional reaction to information material. Women evaluated the 
brochure and video with three items asking about unpleasant, shocking, and 
frightening experiences with this material.  
Need for support/advice. At T4, Women were asked whether they had wanted 
more support and advice from their specialists regarding their treatment choice on a 
seven-point scale (1, strongly disagree; 7, strongly agree). 
 
Analyses 
The psychometric analyses on the decision items were done on the data obtained at T2. 
When women had no breasts because of previous curative or prophylactic surgery, 
answers to decision related questions were coded as not applicable. We did missing 
data analyses on the decision items. Factor analyses were done to uncover factors 
underlying decision evaluation. As factors were expected to be associated, an oblique 
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factor solution was sought in order to arrive at a simple structure solution, discarding 
items that loaded highly on more than one scale. For the Rasch and Reliability 
analyses, items were recoded to obtain positive correlations among items. Rasch 
analyses were done on the items belonging to a single factor [26]. As Rasch models are 
only readily available for dichotomous items, all items were dichotomised by assigning 
the first three response categories to 0, and the two upper categories to 1. Based on the 
final item selection, scores of the items were averaged for each of the three scales. 
Reliability coefficients (Cronbach’s α) were calculated. Tests of construct validity 
were performed by testing hypothesised associations of the Decision Evaluation scales 
with other measures described above. These hypotheses were generated after the scales 
were identified but before the relation of the scales with the remaining measures was 
inspected. We tested hypotheses cross-sectional regarding the data collected at T2 and 
also in mutation carriers at T4. 
For missing items from multi-item scales, we imputed the mean of the 
remaining items when at least half of the items were completed. The number of 
subjects providing data for the various analyses varied due to missing data and due to 
non-applicability of some questions.  
 
RESULTS 
 
Number of participants 
At study entrance (T1), 453 women were eligible and 390 (86%) gave informed 
consent [18]. By T2, 368 were still in the study [21]. Ninety-one women had a 
BRCA1/2 mutation and were therefore eligible for the second part of the study. Three 
women withdrew after the positive genetic test result due to high emotional distress. 
The follow up at T4 and T5 was complete in 88 and 87 women, respectively [21] 
 
Psychometric analyses 
Of the 368 women at T2, 22 women were discarded as both their breasts were already 
removed, either to treat breast cancer that had developed previously to our data 
collection (N = 21), or for preventive reasons (N = 1). Three other women with 
completely missing data were also discarded. Thus data of 343 women remained for 
psychometric analyses. Table 1 presents their socio-demographic data. 
One item “I wish I could stick to my decision” was deleted because of too many 
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missing responses. Of the remaining 35 items, on average, 1.5% of the item responses 
were missing. Out of the 343 women, 299 (87%) completely filled out the remaining 
35 items, and these were subjected to factor analysis. An interpretable oblique solution 
was found containing three factors, explaining 34%, 7% and 6% of the variance in the 
data from 35 items. 
 
Table 1. Demographic and medical characteristics of the participants 
 N % 
Sociodemographics   
     Age (years)    
          40 or younger 148 43 
          41-49 104 30 
          50 or older   91 27 
     Marital status   
           Single    23   7 
          Married or living together 291 85 
          Widowed/Divorced   28   8 
     Employment status   
          Employed 222 65 
          Other 119 35 
     Education   
          Lower than high school   75 22 
          High school 179 52 
          College or higher   82 24 
Personal medical history   
     No cancer 172 50 
     Breast cancer only 153 45 
     Ovarian cancer only   15   4 
     Breast and/or ovarian cancer     3   1 
Familial medical history   
     Breast cancer only 155 50 
     Ovarian cancer only   11   4 
     Breast and/or ovarian cancer 141 46 
     Known familial mutation  47 
     First degree relatives with bc or oc  62 
     First degree relatives died of bc or oc  32 
bc, breast cancer; oc, ovarian cancer 
 
Items in these factors were subjected to Rasch analyses. After further item selection, 
three Rasch scales emerged containing five items each. Rasch statistics are available 
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from the first author. These 15 items were translated into English independently by the 
first author and a professional translator. Discrepancies between the translations were 
resolved by consensus. In view of the item content and the factor loadings, these scales 
were labelled as Satisfaction-Uncertainty, Informed Choice, and Decision Control. 
Higher scores on the Satisfaction-Uncertainty scale indicate higher satisfaction, and 
thus lower uncertainty. The reliabilities (Cronbach’s α) of the three scales were 0.79, 
0.85, and 0.75, respectively. 
The factor analysis on the final item selection is presented in Table 2. The three 
scales explained 39%, 12%, and 8% of the total variance of the final 15 items. For each 
scale, scale values were calculated when responses on three or more items were 
present. Each scale value was available for at least 96% of the 343 women. The 
correlations between the scales were moderate r (Satisfaction-Uncertainty, Informed 
Choice) = 0.52, r (Satisfaction-Uncertainty, Decision Control) = 0.56, r (Informed 
Choice, Decision Control) = 0.41. 
 
Table 2. Factor loadings (Pattern Matrix) of 15 items in three Rasch scales, obtained after oblique rotation 
 Satisfaction-
Uncertainty 
Informed Choice Decision Control 
I expect to stick with my decision -0.83   
I am satisfied with my decision  -0.82   
I am still doubtful about my choice  0.76   
This is my own decision  -0.66   
I find it hard to make this choice   0.60   
    
I am satisfied with the information I received   0.83  
I know the pros and cons of the treatments   0.78  
I want more information about this decision   -0.76  
I want a clearer advice   -0.70  
I made a well informed choice -0.41  0.62  
    
This decision is made without me   -0.84 
I feel pressure from others in making this decision   -0.74 
I wish someone else would decide for me   -0.58 
My decision frightens me  0.29 -0.26 -0.45 
I regret my decision  0.41  -0.43 
* Correlations smaller than 0.25 are suppressed. 
 
Our prior concepts appear to have been only partly confirmed, as the concepts social 
support and approval, effective decision making, and perceived riskiness were not 
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retained in the final Decision Evaluation scales. When we allowed for five factors to be 
extracted (results not shown), social support and perceived riskiness items did yield 
two additional factors. However, these factors added relatively little to the explained 
variance of the variables in the factor analysis, and were therefore not retained. In three 
factor solutions, the items constructed to cover the concepts of social support, 
responsibility, and effective decision making blended with the factor Satisfaction-
Uncertainty. The social support items did not survive further item selection procedures. 
The perceived riskiness items were correlated with the Decision Control scale, but also 
did not survive further item selection procedures. Thus, we conclude that there was 
some evidence for the prior concepts, but these concepts explained little additional 
variance, and blended with the Satisfaction-Uncertainty or Decision Control factors. 
  
Validity 
The scales should be associated with Strength of Preference regarding the treatment 
choices for breast cancer. Higher Strength of Preference was expected to be associated 
with higher Satisfaction-Uncertainty, Informed Choice, and Decision Control scores. 
The results in Table 3, row 1, support these hypotheses. Sample sizes varied from 302 
and 328. 
We hypothesised that Satisfaction-Uncertainty, Informed Choice, and Decision 
Control were associated with improved well-being. The results in Table 3 confirm 
these hypotheses. Decision Control showed the largest associations with well-being. 
We hypothesised that the scales should be associated with the three information 
related measures. We expected that better scores on the three information related 
measures should be associated with higher Satisfaction-Uncertainty, Informed Choice, 
and Decision Control scores. The associations should also be stronger for the Informed 
Choice scale. The results in Table 3, row 6 through 8, support these hypotheses. 
Previously, we found that a negative emotional reaction to a similar video and 
brochure was associated with a more troublesome resolution of decision process [27]. 
We expected that lower scores on Decision Evaluation scales would be related to a 
negative emotional reaction towards the brochure and video. This turned out to be the 
case, Table 3, row 9. Decision Control showed the largest association with a negative 
emotional reaction to the information material. Sample sizes vary from 161 to 163 
because these data are from the intervention group. 
Women were asked whether the partner agreed with their treatment choice. We 
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expected that partner agreement would have a positive effect on the decision 
evaluation. These hypotheses were also confirmed (Table 3, row 10). For row 10, N 
varies from 264 to 268, because not all women had a partner. 
 
Table 3. Correlations of Satisfaction-Uncertainty, Informed Choice, and Decision Control, with Strength of 
Preference, information related and well-being measures, at T2, 4 weeks after blood sampling 
 Satisfaction-
Uncertainty 
Informed Choice Decision Control 
Strength of preference  0.64  0.36  0.39 
    
Anxiety -0.34 -0.25 -0.40 
Depression -0.22 -0.15 -0.30 
Intrusion-Avoidance -0.21  -0.12* -0.28 
General health  0.20  0.20  0.19 
    
Subjective knowledge  0.19  0.52  0.23 
Amount of information  0.27  0.61  0.23 
Satisfaction with quality of information  0.23  0.58  0.22 
    
Negative emotional reaction  -0.19* -0.24 -0.42 
Partner agreement  0.27  0.27  0.20 
* P < 0.02 
All remaining P values < 0.001 
 
Table 4 presents mean scores on the scales split out by treatment choice. Decision 
Evaluation scores were worse in undecided women, (Satisfaction-Uncertainty, 
F(2,325) = 30.89, P < 0.0001; Informed Choice, F(2,323) = 4.35, P = 0.014; Decision 
Control, F(2,325) = 8.33, P = 0.003). 
 
Table 4. Mean scores (SD) for Decision Evaluation scales 4 weeks after blood sampling, for all women, and split 
out by treatment choice 
  Satisfaction-
Uncertainty 
Informed Choice Decision Control 
Entire population 3.63 (0.70) 3.14 (0.78) 2.97 (0.64) 
Prophylactic mastectomy 3.74 (0.60) 3.14 (0.77) 3.02 (0.62) 
Screening for breast cancer 3.71 (0.69) 3.21 (0.81) 3.01 (0.64) 
Undecided 2.73 (0.40) 2.76 (0.54) 2.51 (0.62) 
Responses range from 1 = “strongly disagree” to 5 = “strongly agree”. 
Across the three Decision Evaluation scales, sample sizes vary from: 326 to 328 for the entire population, 121 to 
124 for prophylactic mastectomy, 174 to 178 for screening for breast cancer, 20 to 30 for undecided. 
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After disclosure of the genetic test result, we asked whether more support or a clearer 
advice from the physician was needed. We expected lower Satisfaction-Uncertainty, 
Informed Choice, and Decision Control scores if women indicated the need for more 
support/advice. The results are presented in Table 5, column 2. The results support our 
hypotheses.  
 
Table 5. Correlations of Decision Evaluation scales with need for support and advice, and perceived Strength of 
Preference of physicians, 3 months after a positive test result 
  Need for support/advice Perceived strength of preference by 
physicians 
Satisfaction-Uncertainty -0.36 ** -0.06 
Informed Choice -0.56 ** -0.06 
Decision Control -0.59 **    -0.30 ** 
N-sizes vary from 69 to 77.  
** P < 0.004 
 
We also asked whether women perceived the specialists as holding strong treatment 
preferences. If so, this should be associated with feelings of pressure, one of the items 
in the Decision Control scale. The results in Table 5, column 3, support this 
hypothesis, and for the first time provide support for divergent validity of the Decision 
Control scale as compared to the other two Decision Evaluation scales. 
 
DISCUSSION AND CONCLUSION 
 
We set out to uncover the dimensions involved in the evaluation of medical decisions 
from the patient perspective. We uncovered a new concept measured by the Decision 
Control scale. We confirmed previously uncovered dimensions such as Satisfaction-
Uncertainty and Informed Choice. 
We discuss first the Decision Control Scale. Control is a central concept in the 
health psychology literature [18], and thus, in retrospect, the emergence of this concept 
in the evaluation of medical decisions is not surprising. The separate items of the 
Decision Control scale suggest that feelings of regret, anxiety, and feeling of being put 
under pressure occur in women that are low in Decisional Control. Undecided women 
reported lower levels of Decision Control. In line with findings that control may be a 
resource that aids in resisting stress, Decision Control was the strongest predictor of 
well-being. Women who were low in control proclaimed a strong need for additional 
support and treatment advice, however (and paradoxically), such women also showed a 
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strong negative reaction towards the information material. 
In general, control is viewed as “a measure of relatively stable, cross-situational 
individual differences...” in other words as a relatively stable personality trait or 
disposition [28]. Regret is one of the items in our Decision Control scale. A 
dispositional interpretation sheds a different light on previous studies on regret in 
medical decision making. Brehaut et al [14] found that women with stronger regret 
switched treatments more often. We find that, even before treatment was received, 
undecided women have lower levels of Decision Control, and thus higher levels of 
regret. Likewise, in a retrospective study, Borgen et al [29] studied feelings of regret in 
370 women who underwent prophylactic bilateral mastectomy. Feelings of regret were 
4.26 times more likely when women reported that the discussion about prophylactic 
mastectomy was initiated by the physician. We found a remarkably similar association: 
feelings of regret were 5.03 times more likely when women reported pressure from 
others (another item in the Decision Control scale). But again, this association existed 
before the genetic test result was known, that is long before these women convened 
with the specialists, and thus long before surgery was performed. This analysis 
suggests that regret studies should consider prospective longitudinal study designs to 
control for dispositional explanations. 
Associations between some of the items in our Decision Control scale have 
been reported previously, thus providing independent support for the validity of this 
scale. Brehaut et al [14] developed a regret scale and noted that higher regret occurred 
in those who preferred their physicians to make decisions. We confirm this association 
as regret is in our Decision Control scale as well as two items that deal with whether or 
not the decision is transferred to someone else. Another item in our scale, “I wish 
someone else would decide for me” was similar to an item used by Sainfort and 
Booske [4]. He found that this item was not associated with decision satisfaction, and 
concluded that “the notion of ‘decision responsibility’ or perhaps ‘self-efficacy’ is an 
important and independent element of decision satisfaction”. His conclusion is 
corroborated by our finding that the Decision Control scale, that contained this item, 
was an additional factor of decision evaluation. 
In contrast to previous findings, we found that items from existing uncertainty, 
satisfaction, and effective decision making scales are located on a single scale. We 
believe that this finding is not really at odds with previous findings. For instance, three 
reports [4,9,11] examined uncertainty and satisfaction. O’Connor reported strong 
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correlations between the effective decision making and uncertainty scales, up to 0.66. 
In Sainfort and Booske, one of the items loading on the “satisfaction with choice” 
scale, namely “it was difficult to make a choice”, is similar to the item “this decision is 
hard for me to make”, but the latter item figures in O’Connor’s uncertainty scale. Also, 
Holmes noted a correlation of 0.54 between satisfaction and uncertainty. 
 
Limitations 
One may question the applicability of our items to decisions that are not final. For 
instance, satisfaction with a decision (not the process of decision making) and regret 
are commonly thought to be associated with experiencing good or bad outcomes from 
a decision, and not with the decision itself. The reader may therefore feel that assessing 
satisfaction or regret about a decision not yet made is premature. However, regret also 
occurs when one realizes that good outcomes of a foregone option are no longer 
possible, that is before outcomes are experienced [16,30].  Specifically, Brehaut et al 
[14] defines decision regret “as remorse and distress over a decision”, and not over the 
outcome. A similar distinction between decision evaluation and outcome evaluation is 
made in consumer research [4], namely between post-decision and post-purchase 
satisfaction. In our case, for instance, consider a woman who has chosen prophylactic 
mastectomy and waits for surgery. She may be coping with the future loss of her 
breasts. She may regret the loss of her breasts, which she could have kept had she 
chosen the foregone option of breast screening. Furthermore, the data suggested that 
few women experienced problems answering our satisfaction and regret questions. The 
satisfaction and regret items were skipped by only 5 and 10 out of 343 women, 
respectively.  
 
Practice implications 
We found that Satisfaction-Uncertainty and Informed Choice were important 
dimensions of decision evaluation. The Decision Evaluation scales in turn were 
moderately associated with well-being. These associations with well-being were even 
stronger after a positive test result (up to 0.53). Counsellors and clinicians should 
therefore consider to refer women with low scores on the Decision Evaluation scales to 
a psychologist. An easy way to check for low Decision Evaluation scores is to ask 
whether a decision has been made because undecided women (about 8%) scored worse 
on the Decision Evaluation scales.  
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DISCUSSION 
 
This thesis addresses the impact of a shared decision making program, consisting of 
two decision aids, in women testing for a BRCA1/2 mutation. The decision aids were 
developed to improve decision making in women facing the difficult choice between 
screening and prophylactic surgery for the breasts and/or ovaries because of their high 
genetic risk for breast- and ovarian cancer. In the following section, based on the 
results of the studies reported in this thesis, clinical recommendations for genetic 
counseling are given per chapter. Furthermore, the effectiveness and feasibility of the 
two decision aids are discussed, and suggestions for further research are made.  
 
Clinical recommendations 
 
Chapter 2 
Thus far, most attention is given to prophylactic mastectomy to prolong life. However, 
the results of our decision model point towards a more prominent role for prophylactic 
oophorectomy. Therefore, oophorectomy should be seriously considered as a 
prophylactic option to reduce both ovarian and breast cancer risk. Prophylactic 
oophorectomy has many advantages over prophylactic mastectomy: it does not cause 
visible mutilation, the prognosis of ovarian cancer and the efficacy of ovarian cancer 
screening is worse than of breast cancer. Furthermore, prophylactic mastectomy 
becomes less attractive as recent data support the ability of high-quality magnetic 
resonance imaging (MRI) to detect early stages of breast cancers, which may lead to 
survival benefit [1-3]. Still, the decision about prophylactic oophorectomy could be 
difficult for many premenopausal women because of concerns and controversy about 
the use of hormone replacement therapy (HRT) for menopausal complaints following 
oophorectomy. However, in a recently published decision analysis, evaluating the 
impact of HRT (to age 50 years) on five major diseases (breast and ovarian cancer, 
osteoporosis, coronary heart disease, venous thromboembolism) only small reductions 
in life expectancy were found [4]. The recommendation of oophorectomy as a 
prophylactic option to reduce both ovarian and breast cancer risk, if necessary followed 
by HRT, should explicitly be discussed in the genetic counseling process. This is 
particularly the case for women with a BRCA1 mutation as their lifetime risk of 
ovarian cancer is higher compared to BRCA2 mutation carriers [5] and as they are 
more likely to develop estrogen receptor-negative cancers [6]. 
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Chapter 3 
Protocols for psychosocial care in genetic counseling for a possible BRCA1/2 mutation 
have been mainly tailored towards unaffected women, analogous to the protocol for 
Huntington disease [7]. Previous research on BRCA1/2 testing, mostly concentrating 
on unaffected women, did not find elevated distress not even after testing positive for a 
BRCA1/2 mutation [8-11]. In contrast, our study, that included both affected and 
unaffected women, indicated elevated stress levels after a positive test result, 
especially in affected women. Based on our results, we suggest to focus more on the 
group of affected women and to stimulate contact with a psychosocial worker for 
support especially after receiving a positive test result. If necessary, cutting back 
psychosocial care on unaffected women could be justified. Unfortunately, our research 
does not permit us to give specific recommendations about the form of psychosocial 
support for affected women. This should be a topic for further research. 
 
Chapter 4 
Traditional health education material on genetic testing for a BRCA1/2 mutation is 
already available during genetic counseling. We showed that our informative decision 
aid (DA) led to better informed decision making. One could dispute the value of 
providing the informative DA before the test result, as many women will ultimately 
receive a negative or inconclusive test result. These women have to invest time and 
thoughts into decisions that may not even be necessary. However, because of the 
beneficial effects on information related outcomes without increasing distress, we 
think it is also helpful in the waiting period. Therefore our advice is to offer the 
brochure and video, in addition to genetic counseling, to all women on a voluntary 
basis after taking the blood sample, while making clear that the information is also 
available after the test result. Our brochure has been updated recently upon request of 
the Dutch Cancer Society and can be obtained from them in the future. Many Family 
Cancer Clinics already have purchased our video for use in their genetic counseling 
process.   
 
Chapter 5 
Our results suggested a more thoughtful and deliberated choice following the shared 
decision making intervention (SDMI), which contained a values clarification exercise. 
Trading quality and length of life between treatment options seems to be effective in 
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improving decision making. Furthermore, women reported improved well-being. 
Therefore, it would be desirable to systematically explore individual values for the 
treatment options during genetic counseling. As formal methods of value elicitation, 
such as the time-trade-off method, are alien to daily clinical practice, decision making 
might be improved by eliciting patient’s values in a less formal way for instance by 
prioritizing attributes of treatment options in order of importance or by using a decision 
board were the treatment options and their attributes are summarized [12]. Of course, 
women first need to be fully informed about the treatment options and their 
consequences. Contrary to the informative DA, which is advised for all women, 
caution is called for when offering the SDMI to affected women, as it tended to 
produce detrimental effects.  
 
Chapter 6 
Lower scores on the Decision Evaluation scales were associated with worse well-
being, especially after testing positive for a BRCA1/2 mutation. This suggests referral 
of women with low scores for psychosocial support. However, these Decision 
Evaluation scales are not administered in daily practice. An easier way to check for 
low scores is to ask whether a decision has been made because undecided women 
scored worse on the Decision Evaluation scales. 
 
Effectiveness and feasibility of DAs  
Several types of DAs exist. Including value clarification into the DA, however, is an 
understudied area [13]. The issue of what type of DA is most effective is still 
unresolved [14]. Our randomized study shed some light on this issue. The informative 
DA showed beneficial effects on information related outcomes only, while the SDMI 
showed beneficial effects on other outcomes namely well-being and decision related 
outcomes. Thus the effects are complementary. In a previous uncontrolled before-after 
study of our group, the informative DA and the SDMI were evaluated as one package 
[15]. Then, beneficial effects were found on information related outcomes as well as 
on more general outcomes, suggesting that the beneficial effects of these two 
interventions add-up. This is the first time that the complementary character of these 
two different interventions has been reported in a clinical population. The conclusion is 
that to improve the decision making process, more is needed than just information. In 
addition, one needs to involve the patient in tradeoffs between various treatment 
options. Thus, preferably, the complete support package should be offered. Next to 
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establishing the essential elements of a DA, it is also important to identify the people 
who are most likely to benefit as different effects were found in unaffected versus 
affected women.  
Most women judged the informative DA positively and stated that it contained 
exactly enough information. Only few women (2%) did not view the informative DA 
because of an emotional burden. Although the brochure included 14 pages and the 
video took 45 minutes, half of the women viewed it twice or more. Furthermore, while 
they were now more fully informed about the consequences of a positive test result, 
none of the women declined to receive their test result. In the research setting, the 
informative DA was sent to the women by mail. In daily clinical practice, it would be 
feasible to offer the informative DA on a voluntary basis during genetic counseling.  
All women who have been randomized to the SDMI group were able to answer 
the TTO-questions, and could understand their individualized treatment information 
based on life expectancy and quality adjusted life expectancy. Most women were 
satisfied with the SDMI because they felt that their own thoughts came out in the 
SDMI. Although the SDMI was quite time-consuming, e.g. the first TTO-interview 
took about one hour, none of the women withdrew from the study for that reason. 
Despite the compound and intensive mode of the intervention, it was feasible to 
implement in clinical daily practice when performed by a well-trained research-nurse 
within a research context. The decision model is easy to run by a researcher at least for 
unaffected women; for affected women the prognosis of their former cancer has to be 
retrieved and implemented in the model. Outside the research setting, decision analysis 
is already becoming more routine and accepted to determine generic treatment policy. 
Decision analyses do not yet have a prominent place in daily clinical practice. Our 
results showed although that it can serve as a clinically useful framework for 
counseling. Time constraints make it unrealistic to conduct a separate decision analysis 
for each patient. However, in the future, with increasing computerization in clinical 
practice, along with the development of user-friendly software, formal utility 
assessment and decision analyses may be a more realistic aim for decision making with 
individual patients in daily clinical practice.  
To be of further use in daily clinical practice, the risk figures used in the 
brochure and in the decision model should be kept up to date as new research in this 
field is still emerging. It is important that the risk figures in the brochure agree with the 
figures in the decision model. Furthermore, all clinicians should counsel the same risk 
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figures. From personal reports, we know that discordant information on the efficacy of 
treatment options causes a lot of unnecessary distress.  
 
General conclusions and directions for future research 
Our shared decision making study improved decision making. The simpler, more easy 
to implement, informative DA was effective on improving information related 
outcomes while the more complex SDMI was effective on improving decision related 
and well-being outcomes. Ideally both should be offered as one complete package. 
However, as it seems unrealistic to implement the SDMI in clinical daily practice in 
short term, it would be of value to test a simpler version of the SDMI to see whether it 
is equally effective. Another important finding in our study was that affected women 
reacted more distressed towards a positive test result and experienced detrimental 
effects from the SDMI. Because we were not able to explain these reactions, further 
research is needed in order to make specific recommendations about the contents of 
additional support for affected women.  
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SUMMARY 
 
In this thesis, the effects of a shared decision making program were evaluated in 
women testing for a BRCA1/2 mutation. Women with a BRCA1/2 mutation have a 
high genetic risk of developing breast and ovarian cancer. They face the difficult 
choice between screening and prophylactic surgery for the breasts and ovaries. The 
shared decision making program consisted of two decision aids. The decision aids have 
been developed as adjuncts to standard genetic counseling to prepare women for 
decision making.  
 
Chapter 1 provides a general background of shared decision making and decision aids, 
the BRCA1/2 mutation, genetic testing and counseling, the treatment options for 
women with a BRCA1/2 mutation, and decision analysis. The aim of this thesis is also 
discussed. 
 
Chapter 2 describes the development of a decision model. It addresses the question 
which treatment option is preferred for BRCA1 mutation carriers. Four treatment 
options (prophylactic mastectomy and prophylactic oophorectomy, screening for breast 
cancer and prophylactic oophorectomy, prophylactic mastectomy and screening for 
ovarian cancer, and screening for breast and ovarian cancer) were compared with 
respect to their effect on (quality adjusted) life expectancy. The analysis was 
performed for a high (85% risk of breast cancer, 63% risk of ovarian cancer) and 
medium (56% risk of breast cancer, 16% risk of ovarian cancer) risk level. Data used 
in the model originated from the literature. Recent data suggesting an interaction 
between oophorectomy and breast cancer risk were incorporated. Utilities for the 
health states after prophylactic surgery were obtained from mutation carriers. 
Sensitivity analyses were conducted to assess the impact of alternative assumptions. 
Life expectancy was highest after prophylactic mastectomy together with prophylactic 
oophorectomy. However, if patient preferences were taken into account, prophylactic 
oophorectomy alone tends to be a better strategy in most women at medium risk and in 
young women at high risk when performed before age 40. These results point towards 
a more prominent role for prophylactic oophorectomy in BRCA1 mutation carriers.   
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Chapter 3 evaluates the impact of testing for a BRCA1/2 mutation and disclosure of a 
positive test result. Both women affected and unaffected with cancer, testing for a 
BRCA1/2 mutation, were included. Data were collected during a longitudinal 
randomized trial on shared decision making. The baseline assessment was 1 week after 
blood sampling for BRCA1/2 testing (affected women n = 192, unaffected women n = 
176). The follow-up assessment was 2 weeks after receiving a positive test result 
(affected women n = 23, unaffected women n = 66). Data were collected on well-being 
(anxiety, depression, cancer related distress, general health), treatment choice, and 
decision related outcomes (strength of treatment preference, decision uncertainty, 
preference for decision making) using questionnaires. Receiving a positive test result 
led to a worse well-being, a stronger treatment preference, and less decision 
uncertainty. There was a tendency towards a more profound impact on well-being in 
affected women. Women diagnosed with cancer less than one year ago reported higher 
general and cancer related distress than those diagnosed longer ago. Affected women 
could benefit from psychosocial support, especially after testing positive. 
 
Chapter 4 assesses the impact of a decision aid (DA) and its timing for women being 
tested for a BRCA1/2 mutation. The DA consisted of a brochure and video providing 
information on screening and prophylactic surgery and their consequences. In a 
randomized trial, the DA (n = 184) was compared to usual care (n = 184). Women 
received the DA 2 weeks after blood sampling for genetic testing. To evaluate the 
impact of timing, mutation carriers who had received the DA before the test result (n = 
47) were compared to mutation carriers who received the DA after the test result (n = 
42). The same data were collected as in Chapter 3. Additionally, data were collected on 
information related outcomes (subjective knowledge, satisfaction with the amount and 
the quality of information, risk perception). The follow-up assessments were 4 weeks 
after blood sampling (impact of the DA) and 2 weeks after receiving a positive test 
result (impact of timing of the DA). The DA had no impact on well-being neither on 
decision related outcomes. Beneficial effects were found on the information related 
outcomes. These effects occurred irrespective whether the DA was presented before or 
after the test result. No interaction effect was found between the DA and the personal 
history of cancer. We conclude that women being tested for a BRCA1/2 mutation 
benefit from the DA on information related outcomes. Because timing had no effect, 
the DA is considered useful either before or after the test result. 
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Chapter 5 reports the impact of a shared decision making intervention (SDMI) for 
BRCA1/2 mutation carriers. The SDMI consisted of two value assessment sessions, 
using the time trade-off method, followed by individualized treatment information 
based on (quality adjusted) life expectancy. After the baseline assessment (2 weeks 
after a positive test result), women were randomized to the SDMI group (n = 44), 
receiving the SDMI 2 months after the test result, or to the control group (n = 44). The 
short and long term effects of the SDMI were assessed using questionnaires at 3 and 9 
months after the test result. The same data were collected as in Chapter 3. Additionally, 
data were collected on the feeling of having weighed the pros and cons of the treatment 
options. The SDMI only had an effect on the long term. Women reported less intrusive 
thoughts about cancer, a better general health, and tended to be less depressed. 
Furthermore, the SDMI strengthened treatment preferences and increased the feeling 
of having weighed the pros and cons. A differential impact was found in affected 
versus unaffected women. Unaffected women benefited from the SDMI, while affected 
women tended to experience detrimental effects. We conclude that supporting decision 
making in a systematic way using trade offs is beneficial for unaffected women.     
 
Chapter 6 describes the development of the Decision Evaluation scales. The Decision 
Evaluation scales were meant to assess the effects of decision aids. A new concept was 
uncovered namely Decision Control, alongside previously known dimensions as 
Satisfaction/Uncertainty and Informed Choice. Decision Control was the strongest 
predictor of well-being. This new scale is a promising measure to monitor the effects 
of interventions to improve shared decision making.  
 
Chapter 7 provides clinical recommendations for genetic counseling per chapter. The 
effectiveness and feasibility of the two decision aids are discussed, and suggestions for 
further research are made.  
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SAMENVATTING 
 
Dit proefschrift evalueert de effecten van een programma voor gezamenlijke 
besluitvorming (shared decision making (SDM)) bij vrouwen die zich laten testen op 
een BRCA1/2 mutatie. Vrouwen met een BRCA1/2 mutatie hebben een erfelijk 
verhoogd risico op borst en eierstokkanker. Zij staan voor de moeilijke keuze tussen 
screening en preventieve chirurgie van de borsten en eierstokken. Het SDM 
programma bestond uit twee hulpmiddelen voor SDM, zogenaamde decision aids. De 
decision aids zijn ontworpen om te worden toegevoegd aan de standaard genetische 
counseling om vrouwen voor te bereiden op het nemen van een beslissing.  
 
Hoofdstuk 1 beschrijft de algemene achtergrond van shared decision making en 
decision aids, de BRCA1/2 mutatie, genetisch testen en counseling, de 
behandelingsopties voor vrouwen met een BRCA1/2 mutatie en besliskundige analyse. 
Het doel van dit proefschrift wordt ook besproken. 
 
Hoofdstuk 2 beschrijft de ontwikkeling van een besliskundig model. Het beoogt de 
vraag te beantwoorden welke behandelingsoptie de voorkeur verdient voor draagsters 
van een BRCA1 mutatie. Vier behandelingen (profylactische mastectomie en 
oophorectomie, screening op borstkanker en profylactische oophorectomie, 
profylactische mastectomie en screening op eierstokkanker, en screening op borst- en 
eierstokkanker) werden met elkaar vergeleken met betrekking tot hun effect op de 
(kwaliteitsgecorrigeerde) levensverwachting. De analyse werd uitgevoerd voor een 
hoog (85% risico op borstkanker, 63% risico op eierstokkanker) en medium (56% 
risico op borstkanker, 16% risico op eierstokkanker) risico niveau. Het model is 
gebaseerd op gegevens uit de literatuur. Recente gegevens die duiden op een interactie 
tussen oophorectomie en de kans op borstkanker werden geincludeerd. Utiliteiten voor 
de gezondheidstoestanden na profylactische chirurgie werden gemeten bij draagsters 
van een mutatie. Gevoeligheidsanalyses werden uitgevoerd om het effect van 
alternatieve aannames te evalueren. De levensverwachting was het hoogst na 
profylactische mastectomie gecombineerd met profylactische oophorectomie. Echter, 
rekening houdende met de voorkeuren van patiënten, lijkt profylactische 
oophorectomie een betere strategie voor de meeste vrouwen met een gemiddeld risico 
en voor jonge vrouwen met een hoog risico, wanneer dit wordt uitgevoerd voor de 
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leeftijd van 40. Deze resultaten duiden op een belangrijke rol van profylactische 
oophorectomie voor draagsters van een BRCA1 mutatie.  
 
Hoofdstuk 3 bespreekt het effect van het testen op een BRCA1/2 mutatie en het 
ontvangen van een positief test resultaat. Zowel vrouwen met als zonder kanker, die 
zich lieten testen op een BRCA1/2 mutatie, werden geincludeerd. De gegevens zijn 
verzameld gedurende een longitudinale gerandomiseerde studie betreffende shared 
decision making. De baseline meting vond 1 week na bloedafname voor het testen op 
een BRCA1/2 mutatie plaats (vrouwen met kanker n = 192, vrouwen zonder kanker n 
= 176). De follow-up meting vond 2 weken na het ontvangen van een positief test 
resultaat plaats (vrouwen met kanker n = 23, vrouwen zonder kanker n = 66). Met 
behulp van vragenlijsten werden gegevens verzameld over het welbevinden (angst, 
depressie, kanker gerelateerde stress, algemene gezondheidstoestand), de 
behandelkeuze, en beslissingsgerelateerde uitkomstmaten (sterkte van de 
behandelingsvoorkeur, onzekerheid betreffende de behandelingskeuze, wens tor 
participatie in het beslisproces). Het ontvangen van een positief test resultaat leidde tot 
een verminderd welbevinden, een sterkere behandelingsvoorkeur en minder 
onzekerheid over de behandelingskeuze. Het leek erop dat het negatieve effect op het 
welbevinden sterker was voor vrouwen met kanker. Vrouwen waarbij de diagnose 
kanker in het afgelopen jaar werd gesteld, rapporteerden meer algemene en 
kankerspecifieke stressklachten dan diegene waarbij de diagnose langer geleden werd 
gesteld. Vrouwen met kanker zouden baat kunnen hebben bij psychosociale 
begeleiding, in het bijzonder na een positief test resultaat.  
 
Hoofdstuk 4 evalueert het effect van een decision aid (DA) en het tijdstip van 
aanbieden bij vrouwen die zich laten testen op een BRCA1/2 mutatie. De DA bestond 
uit een brochure en video met daarin informatie over screening en profylactische 
chirurgie en de consequenties daarvan. In een gerandomiseerde trial werd de DA (n = 
184) vergeleken met de standaard zorg (n = 184). Vrouwen ontvingen de DA 2 weken 
nadat bloed werd afgenomen voor genetisch testen. Om het tijdstip van aanbieden te 
evalueren werden mutatiedraagsters die de DA voor de testuitslag hadden ontvangen (n 
= 47) vergeleken met mutatiedraagsters die de DA ontvingen na de testuitslag (n = 42). 
Dezelfde gegevens werden verzameld als in hoofdstuk 3. Additionele gegevens werden 
verzameld betreffende informatiegerelateerde uitkomstmaten (subjectieve kennis, 
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tevredenheid met de hoeveelheid en de kwaliteit van de informatie, risicoperceptie). 
De follow-up metingen vonden 4 weken na bloedafname (effect van de DA) en 2 
weken na het ontvangen van een positief test resultaat (effect van het tijdstip van  
aanbieden van de DA) plaats. De DA had geen effect op het welbevinden nog op de 
beslissingsgerelateerde uitkomstmaten. Op de informatiegerelateerde uitkomstmaten 
werden positieve effecten gevonden. Deze effecten waren onafhankelijk van het 
aanbieden van de DA voor af na het test resultaat. Tussen de DA en de persoonlijke 
voorgeschiedenis van kanker werden geen interactie-effecten gevonden. 
Geconcludeerd wordt dat vrouwen die zich laten testen voor een BRCA1/2 mutatie 
baat hebben bij de DA op het gebied van informatiegerelateerde uitkomstmaten. 
Omdat het tijdstip van aanbieden geen effect had, kan de DA zowel voor als na de 
testuitslag worden aangeboden.  
 
Hoofdstuk 5 bespreekt het effect van een shared decision making interventie (SDMI) 
bij draagsters van een BRCA1/2 mutatie. De SDMI bestond uit twee 
preferentiemetingen met behulp van de time tradeoff methode, gevolgd door een 
individueel behandeladvies gebaseerd op (kwaliteitsgecorrigeerde) levensverwachting. 
Na de baselinemeting (2 weken na een positief test resultaat) werden vrouwen 
gerandomiseerd naar de SDMI groep (n = 44), de SDMI werd 2 maanden na een 
positief testresultaat aangeboden, of naar de controlegroep (n = 44). Korte en lange 
termijn effecten werden gemeten met behulp van vragenlijsten op 3 en 9 maanden na 
het test resultaat. Dezelfde gegevens werden verzameld als in hoofdstuk 3. Additionele 
gegevens werden verzameld over het gevoel een afgewogen keuze te hebben gemaakt. 
De SDMI had alleen effect op de lange termijn. Vrouwen hadden minder vaak zorgen 
over kanker, een betere algemene gezondheidstoestand en leken zich minder depressief 
te voelen. Verder versterkte de SDMI de behandelingsvoorkeur en het gevoel een 
afgewogen keuze te hebben gemaakt. Voor vrouwen met en zonder kanker werd een 
verschillend effect gevonden. Vrouwen zonder kanker profiteerden van de SDMI, 
terwijl vrouwen met kanker nadelige effecten leken te ervaren. Geconcludeerd kan 
worden dat besliskundige ondersteuning op systematische wijze, gebruik makende van 
trade offs, een positief effect heeft bij vrouwen zonder kanker.  
 
Hoofdstuk 6 beschrijft de ontwikkeling van de Beslisevaluatie schalen. De 
Beslisevaluatie schalen hadden tot doel het effect van decision aids te evalueren. Een 
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nieuwe factor werd ontdekt namelijk Controle over de Beslissing, naast al bestaande 
schalen zoals Tevredenheid/Onzekerheid en Geïnformeerde Keuze. Controle over de 
Beslissing was de sterkste voorspeller van welbevinden. Deze nieuwe schaal wordt 
aangeraden voor de evaluaties van interventie ter verbetering van shared decision 
making.  
 
Hoofdstuk 7 geeft klinische aanbevelingen voor genetische counseling. De effectiviteit 
en bruikbaarheid van de twee decision aids worden besproken en suggesties worden 
gedaan voor toekomstig onderzoek. 
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